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Abstract
Introduction
Colorectal cancer (CRC) is one of the most common cancers in the Western world. Screening for 
CRC using faecal occult blood test (FOBT) is well established. There is evidence that DNA based 
stool tests may be more effective than FOBT.
Hypothesis
The hypothesis is that in patients with CRC, rectal mucus may contain DNA derived from colonic 
tumours. It is speculated that quantitative or qualitative assessment of DNA in rectal mucus may 
permit an improved method of CRC screening.
Aims
Using surgically resected specimens of colonic tumours:
 To assess the feasibility and reliability of measuring DNA in mucus samples
 To compare different devices to measure mucus DNA
 To assess the amount of mucus DNA at various distances from colonic tumours
In patients with CRC and controls:
 To compare the amount of DNA in rectal mucus
Using a panel of 3 DNA methylation markers, to compare the rectal mucus  DNA 
methylation profile between patients with CRC and controls
Methods
Surgical colectomy specimens were obtained from 25 patients with CRC. The feasibility and 
repeatability of measuring mucus DNA amounts was established using different buffer solutions, 
different storage techniques and different sampling devices. Mucus DNA amounts were measured at 
tumour sites and various distances proximal and distal to the tumour. 58 patients referred to a 
colorectal outpatient clinic with suspected CRC were assessed. Rectal mucus samples were 
obtained using a balloon device introduced through a proctoscope. All patients were investigated by 
colonoscopy to clarify the presence or absence of a CRC. The amount of DNA in the mucus 
4
samples was measured. The presence of three DNA methylation markers (NDRG4, TFP12 and 
GATA4) was assessed in all samples. All studies were approved by the local ethics committee.
Results
Reliable measurement of DNA from mucus samples was established using balloon, foam and brush 
devices and a cell lysate buffer. Higher amounts of DNA in surgical specimens were found distal to 
tumours compared to proximally. In patients with CRC the amount of DNA in rectal mucus was 
higher than in controls (no disease or benign polyps). The three DNA methylation marker panel had 
a sensitivity of 87% and specificity of 27.5% for the detection of CRC.
Conclusions
The results are consistent with the hypothesis that DNA detected in rectal mucus is derived from 
proximal tumours. Higher levels of rectal mucus DNA are obtained from patients with CRC than 
from controls. The selected DNA methylation panel was not sufficiently useful in our sample group 
to be of use as a screening technique, due to poor specificity. Further work is in progress to compare 
DNA abnormalities in resected tumour tissue with DNA from rectal mucus in the same patients. 
Future work may be required to improve the panel of DNA abnormalities assessed.
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1.1  Overview of Colorectal Carcinoma
1.1.1. Epidemiology
Colorectal cancer (CRC) is the second commonest cause of cancer related mortality in men 
worldwide1,2 with almost 100 people diagnosed with Colorectal Cancer (CRC) everyday in the 
UK1,2. According to the latest population statistics, in 2008 there were 39,991 new cases of CRC 
diagnosed in the UK, 25,551 of which were colonic and the remainder rectal. The incidence of CRC 
is strongly associated with patient’s age. The majority of cases (60%) are found in people over the 
age of 60 and up to the age of 50 the incidence is equal between men and women. From then on 
men have increased incidence up until the age of 84 when women take over, which can be 
explained by the higher proportion of women in the general elderly population. The overall male to 
female ratio in CRC is 11:10. Incidence of CRC in the UK has been increasing across all age groups 
since the 1970s by about 20% and in the 60-69 age group there is a sharp  increase of 11% in the 
period since 2006 when the national screening program was rolled out1. 
At the same period in the European Union there were 334,000 new cases of CRC diagnosed with 
the highest rate seen in Hungary and Denmark for men and women respectively2. This reflects an 
increasing trend in the incidence of CRC in Europe3,4. Interestingly the incidence of CRC has been 
decreasing in the US since its peak in the mid 1980s5. The reason behind the reduction in incidence 
in the US is unclear although increased use of hormone replacement6 and aspirin7 at the same time 
period have been thought to be possible reasons. The worldwide incidence of CRC is highest in 
industrialized economies although there is an increasing trend in less developed countries which 
have started adapting to a Western lifestyle and diet8. Overall it is estimated, based on current 
incidence, that up to 6% of the Western population will develop CRC in their lifetime5.
In Great Britain the latest mortality  statistics in 20081 showed 16,259 deaths from CRC in total, 
with 10,164 from colon cancer and the majority  of cases (80%) in the over 65 age group. The age 
standardised mortality rate was 17.7/100000 population for CRC, 10.9 for Colonic and 6.9 for rectal 
cancers. Unlike incidence, CRC associated mortality has been decreasing in the UK since the 
1970s9 with a similar trent in the EU10 and US5 as well. This reflects great advances in both the 
diagnosis and treatment of the disease, but also in the understanding of the pathophysiology of CRC 
and implementation of prevention and screening programs worldwide.
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1.1.2 Pathogenesis
In the late 1980s Vogelstein et al11 described the genetic changes of the adenoma-carcinoma 
sequence as the basis of carcinogenesis of CRC. In summary they correlated these genetic changes 
to a model of tumourogenesis where there is development of adenoma from normal colonocytes 
(Figure 1.1) and subsequent progression to an adenocarcinoma. This process is the result of 
mutational activation of several oncogenetic genes and silencing of other tumour suppressor genes, 
that take place at different time points in the adenoma-carcinoma sequence. The initial step is 
inactivation of the adenomatous polyposis coli (APC) gene leading to the appearance of an 
adenoma. Following that a KRAS  mutation allows the adenoma to grow further and when several 
genetic alteration take place in chromosome 18q and p53takes place the adenoma has become a 
carcinoma11,12.
Further understanding of the pathophysiology of CRC has led to classification of CRC 
carcinogenesis into three main different pathways. These are the chromosomal instability pathway 
(CIN), the micro satellite pathway (MSI) and the CIMP  pathway which involves hypermethylation 
of CpG islands resulting in gene silencing. Unfortunately these pathways are not mutually exclusive 
of each other, resulting in tumours expressing features of more than one pathway.
Chromosomal Instability pathway (CIN)
The term CIN can be explained as an increased rate of loss and gain of whole or parts of a 
chromosome resulting in genetic cellular instability13. The result of CIN is aneuploidy 
(chromosomal number imbalance), high frequency of loss of heterozygosity (LOH) and sub-
chromosomal genomic amplifications14. 
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Figure 1.1: The adenoma-carcinoma sequence. Adapted from Fearon ER et al 199012
Normal 
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Adenoma
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Late 
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Metastasis
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Chromosome 12
Mutation in DCC
Chromosome 18
Mutation in p53
Chromosome 17
Inactivation of APC
Chromosome 5
Tumour Progression Neoplasia
The CIN pathway  is the combination of a characteristic set of genetic mutations in CRC in the 
presence of chromosomal instability. The big question of whether CIN causes these mutations or is 
CIN the result of such mutations is yet to be answered. The main mutations involved in the CIN 
pathway are APC, K-RAS, TP53, 18q loss and there also frequent over expression of 
Cyclooxygenase-2.
Somatic APC mutation is found in up to 75% sporadic CRC15,16 and activation of the Wnt signaling 
pathway is considered one of the earliest events in CRC tumourogenesis17. APC inactivation is 
mainly due to mutation although hypermethylation of its promoter has also been reported18. The 
result of APC inactivation is increased cytoplasmic levels of β-Catenin which then translocates to 
the nucleus triggering transcription of several genes involved in both tumourogenesis and tumour 
progression14.
K-Ras mutation is found in up  to 50% of CRC19. It regulates several cellular functions including 
cell growth, survival, apoptosis, cytoskeleton organisation, cell motility, inflammation and cell 
proliferation14. 
p53 dysfunction is considered as the hallmark of almost all human tumours and is widely 
considered the guardian of the genome. It is a tumour suppressor gene and it controls hundreds of 
genes involved in most cellular functions including apoptosis, cell cycle regulation, cell 
differentiation  and cell migration14. In CRC mutated TP53  is found in 50-75% of cases20.
Allelic loss at chromosome 18q is found in 70% of sporadic CRC12. The exact gene involved is yet 
to be defined although several candidates have been identified14.
Over expression of cyclooxygenase-2 is found in 86% of CRC carcinomas21. Its tumourogenic 
effect can be explained by the increased production of prostagladins (especially  E2) which has been 
seen in both adenomas and carcinomas. PGE2 is involved in tumour proliferation migration, 
survival and invasion22.
Several mechanisms have been proposed to explain the CIN phenotype. One of these involves 
defects in the cellular pathways responsible for ensuring that  the chromosomes segregate accurately 
during cell division (equal number of chromosomes distributed to each daughter cell) leading to 
aneuploidy. Abnormal number and function of centrosomes, which coordinate the formation and 
function of the mitotic spindle apparatus during cell division, is also proposed as a mechanism of 
CIN. The end result  is again aneuploidy. During chromosomal segregation the ends of the 
chromosomes are protected by  hexameric repeats called telomeres. These sequences are yet another 
possible candidate to explain CIN. Telomere activation, damage or loss has been associated with 
dramatic genome reorganisation and is seen in vitro in CRC of all stages. Another possible cause of 
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CIN is defective cellular DNA damage-repair although the exact mechanism is not fully understood 
yet. Finally CIN is associated with high LOH and although several mechanisms have been 
proposed, the dominant theory is that  LOH is due to mitotic nondisjunction, however the 
relationship between CIN and LOH is still not fully understood14.
Microsatellite instability pathway
Microsatellites are repetitive DNA sequences comprising short reiterated motifs. They were first 
described in CRC in 1993 when it was noted that a percentage of tumours had several deleted DNA 
bands. When these bands were examined more closely  it  was  clear that they were not actually 
deleted but had migrated further down and had shortened in length. They contained simple 
repetitive sequences (microsatellites) and the research groups used the term microsatellite instability 
to describe their observations. These tumours were more likely to be in the proximal colon and had 
a better prognosis23, 24 compared to other CRC tumours.
Further research revealed that 12-18% of all CRC characteristically  had large number of MSI 
mutations that seemed to be arising in the DNA mismatch repair system (MMR) and led to the 
identification of the genes (MSH2, MSH3, MLH1, MSH6, PMS1, PMS2) responsible for Lynch 
syndrome. As a result MSI was associated with inherited CRC despite the fact that the initial 
description of MSI was in sporadic CRC cases. In addition only up to 4% of all CRC is due to 
Lynch syndrome (see section 1.1.3.1) which can not explain why MSI is found in up to 17% of all 
CRC25. Towards the end of the 1990s it was known that most of the sporadic, MSI positive CRC 
had silencing of MHL1 (via hypermethylation26) and PMS2, and a mutation in BRAF27. These 
tumours were clinically different  from tumours in Lynch syndrome. They  occur later in life, about 
half of them have BRAF mutations  and are associated with CIMP (see below). 
In 1997 a classification of MSI tumours was proposed: 
• MSI-High tumours where more than 30% of MS present is mutated. 
• MSI-Low tumours where a tumour had MSI mutations but under the 30% threshold. These 
tumours have microsatellite stable tumour clinical features. 
• Microsatellite Stable tumours (MSS)28. 
The mechanism of tumourogenesis in the presence of MSI involves the same pathways as in non 
MSI CRC tumours but different targets are involved, For example MSI CRC tumours express a 
normal APC gene but have a mutated β-catenin  resulting in impaired APC function. KRAS (Lynch 
syndrome) and BRAF (sporadic MSI) mutations have the same result as their products both act  at 
the mitogen activated kinase signaling pathway involved in epithelial cell proliferation25. 
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CpG Island methylator phenotype (CIMP)
CpG island refers to a CpG dinucleotide which is found at specific sites in the genome. Human 
DNA contains 5-methylcytosine at specific sites depending on the cell type. These sites are 
determined during embryonic development. The pattern of methylation in human DNA is dependent 
on activity of methyltransferases and demethylases. Methyltransferases are able to recognise these 
CpG islands. They are normally found near gene promoters and transcription start  sites. Several 
human tumours including CRC types use high levels of methylation to silence tumour suppressor 
genes29.
In 1999 Toyota et al30 divided CRC into two groups, one with CIMP (CIMP+) and one without 
(CIMP-). Since then several other groups also tried to define CRC based on methylation markers 
and several systems have been proposed, with the most recent ones in 200731 (CIMP1, CIMP2 and 
CIMP-) and in 201032 (high methylation epigenotype (HME), intermediate methylation epigenotype 
(IME) and low methylation epigenotype (LME)). At the moment there is no universally  agreed 
classification of CRC based on methylation markers as new markers are being identified at a high 
rate. However, five markers are considered as the classic CIMP markers which are CDKN2A, 
MINT1, MINT2, MINT31 and MLH1. In 2007 Jass et al33 classified CRC into 5 subtypes based on 
molecular and clinical characteristics: 
• 1. CIMP-H and MSI-H and BRAF  mutations with poor differentiation, proximal tumours 
representing 12% of CRC, 
• 2. CIMP-H, MSI-L or MSS, BRAF mutation, poorly differentiated proximal tumours 
representing 8% of CRC, 
• 3. CIMP-L, MSS or MSI-L, KRAS mutation, well differentiated distal tumours 20% of CRC, 
• 4. CIMP-MSS, TP53 mutation, well differentiated distal tumours 57% of CRC and finally 
• 5. Lynch Syndrome, CIMP-, MSI-H moderately differentiated proximal tumours 3% of CRC. 
Types 1 and 2 are considered chromosomal stable while 3 and 4 have high degree of CIN. These 
types are not mutually  exclusive of each other and there is some overlap between them. A year later 
in 2008 following the publication of a study34 that  demonstrated an inverse relationship between 
CIN and CIMP, it was suggested that the two mechanisms should be independent of each other. A 
further classification of CRC was proposed by Issa JR35 into three groups/mechanism. 
• Group 1 CIMP+ and MSS, 
• Group 2 CIMP + and MSI 
• Group 3 CIN. 
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The first two groups differ in their CIMP+ profile in that the MSS group has more KRAS  mutations 
but can occasionally have BRAF mutations, a worse clinical outcome and is more closely associated 
with villous adenomas. 
In 2006 Suzuki et al36 noted that hypo and hypermethylation of DNA increases with age and such 
changes are also seen in CRC. Several genes (e.g. ESR1 and MYOD) have been shown to be hyper-
methylated in an age related fashion in normal colonic mucosa (these were excluded from the 
original CIMP classification). What causes this age related hypermethylation remains unknown at 
the moment but it is possible to be secondary to environmental factors29.
1.1.3  Risk Factors  
 1.1.3.1 Familial and Hereditary Colorectal Cancer
Up to 20% of CRC is associated with an inherited predisposition as shown by twin studies37 and 
genetic testing studies38. For the majority  of cases of CRC with inherited predisposition, the 
underlying genetic mechanism is well understood, but there is a significant minority for which the 
exact process is not fully understood39.
Lynch Syndrome (hereditary non-polyposis colorectal cancer)
In 1966 Henry Lynch40 reported an increased incidence of colorectal cancer in two kindreds and 
called it  cancer family  syndrome. Later, the terms Hereditary  NonPolyposis Colorectal Cancer 
(HNPCC) and Lynch syndromes were used but lately the latter has been used more frequently. 
About 2-4% of all CRC patients will have Lynch syndrome41.
Patients with Lynch syndrome tend to develop CRC earlier in life than sporadic CRC patients and 
they  rarely have polyposis. In addition there is a higher incidence of proximal tumours compared to 
sporadic CRC cases39. There is an increased incidence of extra-colonic cancers, namely endometrial 
cancer with a lifetime risk of up to 60%42 while the CRC lifetime risk ranges from 50-80%43. Table 
1.1 summarises tumours associated with Lynch syndrome44.
Genetically Lynch syndrome is characterised by  the presence of a germline mutation affecting the 
DNA Mismatch-repair system (hMSH2, hMLH1, hMSH6, hPMS2) which is responsible for 
correcting single base mismatches and insertion deletion loops during DNA replication. These 
mutations are inherited in a autosomal dominant fashion and cause high micro satellite instability 
(MSI-H)39.
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 Site Frequency**
Colon 30-75%
Endometrium 30-70*% 
Stomach 5-10%
Ovary 5-10*%
Urinary Tract 5%
Other (Small bowel, pancreas, brain) <5%
Table 1.1: Tumours associated with Lynch Syndrome44 
*refers to women cancer cases
**Frequency: cumulative cancer incidences
Diagnosis of such patients is difficult as it is not possible to do genetic testing of all family 
members of all CRC patients as these tests are costly and labour intensive .The Amsterdam criteria I 
and II (table 1.2)45 have been developed to assist clinicians in deciding which patients should be 
sent for genetic testing to identify  Lynch Syndrome. Surprisingly up to 50% of families meeting the 
Amsterdam criteria did not  have MMR germline mutations and the tumours were MSI negative46,47 
implying that a large proportion of families with Lynch syndrome do not meet the Amsterdam 
criteria. In such families testing tissue from CRC in family members could assist clinicians to 
diagnose Lynch syndrome. As mentioned above such tests can be expensive, take time and are 
labour intensive and therefore the Bethesda guidelines48 have been used to identify  the patients 
where tumour tissue should be examined for MSI. 
In the cases where the patient and his/her family meet the criteria but the genetic profile does not fit 
that of Lynch Syndrome the term Familial colorectal cancer type X is used46. 
Amsterdam I Amsterdam II
At least 3 relatives with CRC, 
1 has to be 1st degree relative of the other two
At least 3 relatives with Lynch Tumour (Table 1)
1 has to be 1st degree relative of the other two
At least two successive generations involved At least two successive generations involved
At least one CRC <50yrs old At least one CRC <50yrs old
FAP excluded FAP excluded
Histological verification of tumours Histological verification of tumours
Table 1.2: Amsterdam criteria I and II to assist clinicians to identify  families with possible Lynch 
       syndrome45.
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Familial Adenomatous Polyposis (Classic and Attenuated) and MAP
Following Lynch syndrome, FAP is the second most common CRC syndrome in the familial CRC 
group and unlike Lynch syndrome it is characterised by multiple colonic polyps in early 
adolescence. The average age of diagnosis of CRC is 39 years with the majority (95%) of FAP 
patients developing CRC by the age of 50 years39 if they remain untreated. In addition to classical 
FAP, there is attenuated FAP where patients develop  significantly less polyps and CRC at an older 
age with an increased prevalence of proximal tumours49. Both FAP and its attenuated form are due 
to a germline mutation in the APC gene on chromosome 5q (tumour suppressor gene, part of the 
wnt-signaling pathway) that is inherited in a autosomal dominant fashion39. The location of the 
mutation in APC has been correlated with the severity  of polyposis, as well as the presence of extra-
colonic features such as desmoids50. About 25% of FAP cases are the result  of new mutations or de 
novo mutations39. 
Classical FAP is characterised by hundreds of adenomatous colonic polyps at  a young age (15-30yrs 
old)51. Those patients who have between 10-100 adenomatous polyps and usually present at a later 
age, are more likely to have either attenuated FAP or MYH-polyposis (MAP see below) Extra 
colonic polyposis especially of the upper GI tract  is common in FAP with >50% of patients having 
duodenal and about 50% having gastric polyps52. The life-time risk of developing duodenal cancer 
is about 12%53 compared to gastric cancer which is much lower (1%)51 making duodenal 
malignancy the second commonest cause of cancer in FAP and attenuated FAP53. Non malignant 
features of FAP include desmoids (about 10% of FAP patients), osteomas (skull and mandible), 
fibromas, dental abnormalities, epidermoid cysts and others54. These features are less common in 
attenuated FAP. 
MAP is clinically very similar to attenuated FAP, both in the number of polyps present but also in 
the age of onset of CRC and higher proximal lesion incidence55 but unlike FAP or its attenuated 
form, is due to a biallelic MUTYH mutation (mutY human homologue gene on chromosome 1p). 
FAP-associated non malignant features such desmoids etc have not been seen in MAP, although a 
higher incidence of ovarian and badder cancer has been observed39. In addition there is some 
evidence of an association between MAP and both hyperplastic and serrated polyps but this is based 
on a small study56.
17
Hamartomatous Polyposis (Peutz-Jeghers (PJS) and Juvenile Polyposis (JPS) Syndromes)
Hamartoma is defined as a tumour-like, non-neoplastic disordered proliferation of mature tissues 
that are native to the site of origin57. PJS is due to a germline mutation in STK11 while JPS is due to 
mutations in two genes (SMAD4 or BMPR1A) but these mutations are only seen in up to 70% in 
PJS and only 40% in JPS39. 
Both PJS and JPS are characterised by  hamartomatous polyps in the gastrointestinal tract and are 
associated with an increased risk of CRC58. In PJS the dominant site of polyposis is the small 
bowel59 (95% of cases) followed by the colon39 (30% of cases). Small bowel obstruction and PR 
bleeding are the predominant symptoms that usual start in the teenage years with the almost 
pathognomonic feature of buccal and lip pigmentation. A combination of small bowel polyps and/or 
pigmentation and/or family history of PJS is used to diagnose patients. The life time risk of 
developing CRC in PJS patients is estimated60 at 39%. Unlike PJS, JPS does not have any 
pathognomonic features such as pigmentation to facilitate diagnosis and as a result  the diagnosis is 
based on finding more than 3 juvenile polyps in the colon and /or multiple GI polyps or a family 
history of JPS. A minority  of JPS patient have GI arteriovenous malformations as well as 
pulmonary arteriovenous malformations39. The lifetime risk of CRC in JPS61 is 39%.
Hyperplastic Polyposis (HPP) or Serrated Polyposis
Little is known regarding this rare syndrome where there are multiple and/or large colonic polyps. 
The current WHO criteria for diagnosing HPP are 30 cumulative hyperplastic polyps of any  size in 
the colon, or >5 hyperplastic polyps proximal to sigmoid, or at least one hyperplastic polyp in an 
individual with a family history (first degree relative) of HPP. 
HPP is associated with an increased risk of developing CRC and there is an association between the 
number of hyperplastic polyps and the presence of serrated adenomas. The exact genetic 
mechanism of HPP is not yet understood39.
Common Familial Colorectal Cancer
This subgroup of inherited CRC includes patients who have an increased incidence of CRC in their 
family but do not have the high penetrance genetic mutations of the above syndromes. Individuals 
with a first degree relative that had CRC diagnosed <50yrs or two first degree relatives with CRC 
have a 6-fold increase in their lifetime risk of developing CRC62. Several (up  to 170) chromosomal 
regions have been identified63 as possible candidates to explain this increased risk but they all have 
low penetrance unlike the genetically well defined syndromes. As there are no specific genetic 
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markers for this group of patients, specific guidelines based on number of first degree relatives 
diagnosed with CRC and the age that they developed CRC, are used to identify high risk cases39. 
 1.1.3.2  Diet
Fibre
It is has been known for over 40 years that high fibre based diets seem to offer protection against 
CRC64. However the scientific evidence to support that observation appears to be controversial. A 
meta-analysis65 of 37 observational epidemiological studies and 16 case-controlled studies and a 
pooled analysis of 13 case-controlled66 studies concluded that there was a 40-50% reduction in 
CRC risk in individuals with a high fibre diet. 
In contrast, a pooled analysis of 13 prospective cohort studies in 2005 by Park et al67 showed a 
weak association between a high fibre diet and a reduction in risk of CRC, which was lost when 
they  repeated the analysis correcting for other possible dietary factors such folate or Vitamin B. In 
2009 the EPIC study68, a large prospective study showed a 40% risk reduction with a high fibre 
diet. Finally  several randomised controlled studies69-71 where the intervention was a high fibre diet 
(in the form of increased vegetables, supplements and fruit) have showed no difference between the 
intervention and control groups. 
Red Meat 
The evidence that red meat is associated with a higher risk of developing CRC is less controversial 
and mostly universally accepted. The EPIC study in 200572 gave a risk of 1.8% of developing CRC 
in 10 years for a 50 year old eating large amounts of red meat and only 1.3% if less red meat was 
consumed. The mechanism by which red meat exerts its effect  remains unclear at the moment but 
there is some evidence that  red meat which is grilled, fried or cooked at high temperatures is rich in 
heterocyclic amines which are mutagenic and can cause adenoma73.
Carbohydrates
Diets rich in refined carbohydrates can stimulate short lived surges of insulin which in turn can be 
carcinogenic (see below section on obesity) in CRC73. In addition several studies74-76 have 
demonstrated a link between carbohydrates and CRC.
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 1.1.3.3  Lifestyle
Alcohol
A pooled analysis of 8 prospective and case control studies77 and the EPIC study78 both 
demonstrated an increased risk of CRC if >30g/day of alcohol is consumed. It is unclear how 
alcohol leads to carcinogenesis although it  has been suggested that it might contribute to abnormal 
DNA methylation79 or that  it has systemic effects affecting the immunological surveillance of 
tumours or DNA repair mechanisms80. 
Tobacco
Epidemiological studies in the USA have concluded that up to 20% of CRC can be attributed to 
smoking81-83 with the effect seen in ex smokers despite stopping smoking for up to 31 years84. Two 
recent meta-analyses in 2009 demonstrated not only an association between tobacco smoking and 
CRC85, but also a dose response effect with 38% risk with 40 cigarettes/day, and also duration (20% 
increased risk with every 40 years of smoking) and age of initiation of smoking86. The carcinogenic 
effect of tobacco smoking is due to the release of several carcinogens such as nitrosamines, 
aromatic amines, heterocyclic amines and polynuclear aromatic hydrocarbons87.
Obesity 
In 2007 a meta analysis of prospective studies demonstrated an increased risk for both men (33%) 
and women (16%)  with increasing waist circumference and waist to hip  ratio independent of other 
lifestyle factors88. The mechanism behind this effect is unclear but evidence of increased CRC risk 
in patients with diabetes mellitus indicates that mitogenic properties of insulin along with obesity 
associated insulin resistance trigger carcinogenesis  possibly via the release of IGF-189. High levels 
of circulating insulin affects susceptible cells via either direct binding onto insulin receptors or IGF 
receptors by  increasing free IGF-1 levels by  reducing serum IGF binding proteins. Activation of 
such receptors could lead to increased cell proliferation and at the same time reducing apoptosis, 
hence increasing the risk of tumourogenesis73, 90. In 2007 a large prospective study91 showed a 37% 
increase in CRC in patients with high levels of C-peptide (associated with insulin secretion). In 
addition patients with diabetes mellitus have an increased risk of CRC92-94 which further supports 
the above observations.
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Physical activity
The inverse relationship  between physical activity and CRC is well described in many  studies of 
varied design and power95, 96 in a dose response fashion. Recently  a large meta analysis97 showed 
that higher physical reduced the risk of CRC by 30%. Once again the exact mechanism why 
physical activity has such an effect is unclear but it  could be secondary  to the reducing effect of 
physical activity on insulin secretion98,99.
 1.1.3.4  Medications
Aspirin 
There have been several meta-analyses of randomised control trials (RCT) to assess whether a daily 
dose of aspirin is beneficial in reducing CRC risk. In 2007100 a meta analysis looked at two RCTs 
with follow up data of up  to 20 years concluding that daily  high dose (300mg) of aspirin for 5 years 
reduced the incidence of CRC (RR at 10–19 years [0.60; 95% CI, 0.42-0.87]). In 2010 a further 
meta-analysis101 of four RCTs with similar follow up periods (20 years) confirmed the finding of 
the 2007 analysis with a reduction in incidence and mortality  for proximal colon (adjusted 
incidence HR = 0.35; 95% CI, 0.20–0.63; adjusted mortality  HR = 0.24; 95% CI, 0.11–0.52)  and 
rectal (RR = 0.58; 95% CI, 0.36–0.92). It also showed no increased benefit with doses exceeding 
75mg per day for 5 years.  Finally, in 2011, an analysis102 of eight RCTs showed similar results as 
the previous ones and the 20 year HR mortality for CRC was 0.60 (95% CI, 0.45–0.81). This effect 
is most likely  secondary to inhibition of COX-2 and its involvement in CRC carcinogenesis103,104. 
COX-2’s role in CRC carcinogenesis has been shown in animal models where inhibition of COX-2 
has stopped adenoma development in APC mutant  mice, as well as COX-2 and not COX-1 over-
expression in human adenomas and CRC tumours73. Although daily aspirin is beneficial in CRC it 
has a significant side effect profile which almost outweighs this beneficial effect. In 2009 an 
international consensus was published suggesting that further research should be done in high risk 
patients for CRC where maybe its benefit might outweigh its harms105.
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 1.1.4  Diagnosis, staging and prognosis
 Colon and rectal carcinoma is usually diagnosed following a full clinical examination followed by 
investigations that can provide a tissue diagnosis via biopsy of bowel lesions (colonoscopy or 
flexible endoscopy). The patient will then have a CT examination of the chest, abdomen and pelvis 
to assess for distant metastasis and/or synchronous tumours and to contribute to the overall staging 
of the disease. In the case of rectal cancer pre treatment high resolution MRI can provide useful 
information regarding local disease involvement (mesorectal fascia and assessment of the 
circumferential resection margin) and also in treatment decision making. Over the last few years the 
use of endo-rectal ultrasound scan106 has been used more frequently  to assess the depth of bowel 
muscle involvement, allowing more accurate pre treatment staging. The purpose of the pre-
treatment investigations is to allow accurate staging of the disease to guide multidisciplinary teams 
to plan treatment strategy.
Staging of Colorectal cancer
Staging of cancer describes how advanced or severe a person’s cancer is. It allows doctors involved 
with diagnosis and management of cancer patients to plan treatment and to estimate prognosis. In 
colorectal cancer there are two commonly used staging systems. The original Dukes107 system: 
• Dukes A: tumour confined to the bowel wall
• Dukes B: tumour beyond the bowel wall
• Dukes C: lymph nodes involved, Later modified to C1(apical node not involved)  and C2 (apical 
node involved)
• Dukes D: distant metastasis present .
Dukes Stage Relative 5 year survival rate
A 93.2%
B 77.0%
C 47.7%
D 6.6%
Table 1.3 5-year survival rates based on Dukes staging of CRC108.
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The second commonly  used staging system for CRC is the American Joint Committee on Cancer 
(AJCC) TNM109 system:
• T refers to bowel wall involvement:
 TX=primary tumour cannot be assessed 
 T0=no evidence of primary tumour 
 Tis=carcinoma in situ: intraepithelial or invasion of lamina propria 
 T1=tumour invades submucosa 
 T2=tumour invades muscularis propria 
 T3=tumour invades through the muscularis propria into subserosa or into non- peritonealised pericolic or perirectal tissues 
 T4a=tumour penetrates the surface of the visceral peritoneum 
 T4b=tumour directly invades or is histologically adherent to other organs or structures
• N refers to lymph node involvement:
 NX=regional lymph nodes cannot be assessed N0=no regional lymph node metastasis 
 N1a=metastasis in one regional lymph nodes 
    N1b=metastasis in two to three regional lymph nodes
   N1c=Tumour deposits in subserosa, mesentery or non-peritonealised pericolic or perirectal tissues without  regional nodal 
     metastasis
 N2a=metastasis in four to six regional lymph nodes 
 N2b=metastasis in seven or more regional lymph nodes
• M stands for metastatic disease:
 MX=distant metastasis cannot be assessed 
 M0=no distant metastasis 
 M1a=distant metastasis to one site 
 M1b=distant metastasis to more than one site or peritoneum
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Figure 1.2 Survival rate based on staging of Colorectal cancer (Dukes Staging)108
It is not possible to stage patients fully  before treatment starts and clinicians can modify the stage of 
a patient as more information becomes available. In the majority of patients the final staging is 
usually done following histological examination of the surgical specimen. 
TNM Colon 5 year survival rate
Rectal
 5 year survival Rate
T1, T2 N0 97.1% 94.4%
T3 N0 87.5% 78.7%
T4 N0 71.5% 61.4%
T1, T2 N1 87.7% 85.1%
T1, T2 N2 75.0% 63.9%
T3 N1 68.7% 63.3%
T3 N2 47.3% 43.7%
T4 N1 50.5% 47.1%
T4 N2 27.1% 29.5%
Table 1.4: 5-year survival rates based on TNM staging of Colon and rectal caners108-111
The survival rates of CRC depend highly  on the stage of disease (Figure 1.2, tables 1.3 and 1.4 
summarise the latest survival rates using both the Dukes107 and the AJCC TNM systems for colon110 
and rectal111 cancers). 
It is clear from these data that there is a significant  survival benefit with early stage Colon and 
Rectal cancer and therefore early diagnosis and treatment is essential.
It is this survival benefit of early disease detection and treatment along with the presence of a 
premalignant stage in the natural history  of colorectal cancer that make CRC a candidate for 
screening. CRC screening principles, outcomes and challenges will be discussed in detail in the 
next section.
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1.2.  Colorectal Cancer Screening
 1.2.1. Principles of screening for disease
Screening in medicine is unique in that it is a process which aims to identify those individuals 
within a population with an asymptomatic or pre-symptomatic disease. In other words it  is aimed at 
otherwise healthy  individuals. It was defined by the Commission on Chronic Illness (CCI) in 1951 
Conference on Preventive Aspects of Chronic Disease as “the presumptive identification of 
unrecognized disease or defect by the application of tests, examinations, or other procedures which 
can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease 
from those who probably  do not”112. The basic principle behind screening for disease is the 
identification of a disease at an early stage (secondary prevention) to allow early intervention and 
therefore significantly  reduce morbidity and mortality associated with that  particular disease. At the 
same time screening aims to avoid exposing patients to unnecessary  investigation or treatment.  
 In 1968 the WHO identified 10 principles of screening113:
• The condition screened should be an important health problem. As described in the previous 
section (1.1) CRC is a major health problem both based on its prevalence but also as a cause of 
significant mortality and morbidity.
•  There should be an accepted treatment for the condition. The management of CRC has not 
been discussed in this thesis as it is a large topic and not relevant to the content of the thesis. 
However CRC can be successfully treated and as discussed in section 1.1.4 there is a 
significant advantage in early  treatment of CRC as stage at presentation correlates with 
outcome (Figure 1.2, tables 1.3 and 1.4).
• Facilities and resources for both diagnosis and treatment of the disease must be available.
• The disease needs to have a recognisable latent/early symptomatic stage. CRC as demonstrated 
by the adenoma-carcinoma sequence (section 1.1.3.) has a premalignant stage which is 
recognisable and detectable, making CRC a good candidate for screening.
• There should be a suitable test or examination. As described later in this section, at the moment 
there is no perfect screening test for CRC and various screening programs around the world 
use different tests in their screening programs.
• This test needs to be acceptable to the population screened.
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• The natural history of the disease, especially the transition from latent to active (declared) 
disease should be well understood. CRC carcinogenesis is a widely  researched subject with 
constant flow of new information almost on a weekly basis. 
• There should be an agreed treatment policy for patients with the disease.
• The total cost of identifying patients should be balanced against medical expenditure.
• Screening should be continuous and not a once for all process.
There are three types of screening:
• Mass screening: large scale screening of entire population groups.
• Selective screening: screening of a selected high-risk groups. It can be as large scale as mass 
screening depending on the population group selected.
• Multiple screening: screening program where at every  screening episode more than one disease is 
screened for.
Sensitivity and specificity of screening test
The WHO in 1968 also defined how to measure the efficiency of a screening test113. In a screened 
population there are four categories of results:
• those with the disease and with a positive test (true positive)
• those without the disease and a positive test (false positive)
• those without the disease and a negative test (true negative)
• those with the disease and a negative test (false negatives).
Based on the above four categories of results we can define sensitivity and specificity:
                     
                     
       Sensitivity =             
                
                 Specificity =
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True Negatives + False Positives
True Positives
True Positives + False Negatives
True Negatives 
Essentially  sensitivity refers to the ability  of the test to correctly identify those individuals within 
the screened population with the disease (false negative rate) while specificity refers to correctly 
identifying those without the disease (false positive rate).
Bias in screening
In CRC, as in most diseases, tumours detected via screening tend to be diagnosed at an earlier stage 
and therefore should have a better prognosis compared to symptomatic tumours. That does not 
automatically means that this benefit  is purely due to screening because screening has three major 
inherent biases:
• Lead time bias: One of the major aims of screening is to detect asymptomatic disease. It is 
inherent that tumours will be diagnosed earlier than symptomatic tumours.  Therefore the 
survival time since diagnosis is extended compared to symptomatic patients. If in both cases 
patients die at  the same time and we compared the two survival times since diagnosis, the 
screened detected patient will have an apparently improved survival compared to the 
symptomatic patient.
• Length time bias: This refers to the different biological characteristics that screen detected 
tumours may have compared to symptomatic tumours. In other words, screen detected 
tumours may have a slower, less aggressive biological profile to symptomatic tumours.
• Selection bias: Here the bias is due to the different attitude that different  groups of the 
population have towards participation in screening program. Persons with, for example, a 
strong family  history of CRC (higher risk population by definition) are more likely to 
participate in a screening exercise.
The best way to eliminate such biases, is to use large RCTs when evaluating a screening test/
programme. In the next section we will discuss the available and potential screening methods for 
CRC as well as a brief discussion of the current NHS Bowel Cancer Screening Programme 
(NHSBCSP).
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 1.2.2. Methods of Colorectal Cancer Screening
There are several proposed methods of CRC screening, some well established and in current use 
throughout the world, others that are gaining acceptance by  both patients and healthcare 
professionals and others still experimental. They can been grossly  classified into those based on 
stool sampling and those based on structural colonic examinations such as endoscopy or radiology.
! 1.2.2.1 Stool based tests
GuaiacFOBT(gFOBT)
This is the most widely used screening method around the world. It works by detecting blood in the 
stool sample tested, by  testing the peroxidase activity of the haem group of the haemoglobin 
molecule. Therefore it is not specific to only human blood. As described below the 
immunochemical FOBT (FIT) works around that problem by being specific to human 
blood.  A positive gFOBT will trigger a referral for consideration of colonoscopy. 
The main reason gFOBT is so popular with screening programs around the world is that it is simple 
to use by the patient and is relatively low cost compared to other CRC screening tests. The 
detection rates of gFOBT improve significantly if  the patient provides more than one stool sample 
taken on separate days with better results if at least three samples are taken114. Due to its inability to 
distinguish human haem group from dietary  haem (red meat, poultry  etc) and the inhibitory  effect 
of Vitamin C on peroxidase, gFOBT has high false positive and negative rates. In 2011 a Cochrane 
review115 summarised the performance of gFOBT in four RCTs that  involved 372,043 patients in 
four countries (USA, UK, Sweden and Denmark). The screening rounds were mainly biannual 
(Minnesota trial was randomised to annual and biannual) with age groups varying from 45 to 
80years within the four trials. The follow up ranged from 11.7(UK) to 18 (USA) years. Interestingly 
in three trials (USA, Sweden and Denmark) participants were asked to modify their diets prior to 
sampling stool for the gFOBT. In addition,  in two out of the four trials (Sweden, USA) the samples 
were rehydrated prior to analysing the stool samples in the lab as this has been shown to increase 
the sensitivity of the gFOBT116. This was reflected by the low test positivity reported in the non-
rehydrated trials 0.8-3.8% with a positive predictive value for cancer of 5-18.7% compared to the 
other two trials which rehydrated the samples with a test positivity  of 1.7-15.4% and PPV of 0.9% 
to 6.1%. Similarly the test sensitivity was lower in the non hydrated trials (55-57% v 82-92%) as 
28
summarised in Table 1.5. The low PPV for cancer implies that  almost 80% of the positive gFOBT 
were false positive with the majority of the patients being exposed to unnecessary colonoscopy 
(with its associated complications) and psychological stress. However the combined CRC mortality 
reduction from gFOBT screening was 16% with ITT analysis and 25% for those who actually 
attended the screening rounds.
RCTs Rehyd. Positive Rate Sensitivity PPV (CRC) PPV (Aden)
Nottingham No 1.2-2.7% 57.2% 9.9-17.1% 42.8-54.5%
Funen No 0.8-3.8% 55% 5.2-18.7% 14.6-38.3%
Goteborg Yes 1.7-14.3% 82% 4.8% 14.0%
Minnesota
No 1.9% NR NR NR
Yes 3.9-15.4% 92.2% 0.9-6.1% 6.0-11.0%
No 1.4-5.3% 80.8% 5.6% NR
Table 1.5: Sensitivity, PPV for both cancer and adenoma, Rehydration of samples and positivity 
rates for the four RCTs. Adapted from Hewitson P et al116 2008.
The participation rates in the four trials varied with 60-78% of patients attending at least one round 
of screening. The attendance was reduced to 60% in the Swedish trial with subsequent rounds while 
the Danish trial only re-invited those patients that attended the initial screening round yielding very 
high subsequent rounds compliance 94%). In addition, in all four RCTs, staging of the cancers 
detected was significantly  more favourable compared to the control arm with more Dukes As and 
Bs detected (table 1.6) which satisfies the screening test criterion of detecting cancer at earlier 
stage. Interestingly no trial showed any reduction in CRC incidence by using gFOBT screening. 
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Screening Group Control Group
RCTs A B C D A B C D
Notting-
ham 20% 32% 24% 22% 11% 33% 31% 21%
Funen 22% 34% 19% 20% 11% 37% 23% 24%
Goteborg 26% 28% 32% 14% 9% 34% 21% 17%
Minnesota 
A 30% 29% 23% 9% 22% 31% 21% 17%
Minnesota 
B 27% 26% 26% 11% - - - -
Table 1.6: Percentages of CRC stage detected in the two arms of the four RCTs Adapted from 
Hewitson P et al116 2008.
FIT
This test uses antibodies specific to human proteins (haem, albumin or blood components) and has 
therefore lower false positive tests and does not get affected by  diet. In addition only one sample is 
sufficient. It has a sensitivity  of 66-82% in detecting CRC and advanced adenoma (high grade 
dysplasia or polyps more than 1cm) of up to 30% with a high specificity117, 118 of up to 97%. Two 
studies compared FIT and gFOBT in patients participating in screening for CRC, with the 
immunochemical test showing higher detection rates for advanced colonic neoplasia (2.4% v 1.2%) 
and much higher compliance rates of 61%119. More and more countries in the EU have started using 
FIT instead of gFOBT with the Welsh and Scottish screening programs using it as a second line test 
for unclear gFOBT results and with the English program due to switch to FIT over the next few 
years.
Stool DNA tests
Stool DNA testing aims to detect  DNA exfoliated by  CRC tumours and adenomas into the bowel 
lumen and incorporated within the stool. That DNA then needs to be isolated from the stool and 
tested for markers to detect  CRC or advanced adenoma. As described previously in section 1.1.2 the 
genetics of CRC are highly complex and not yet fully understood which does not allow for a 
universal marker to be used to detect CRC or advanced adenomas. As a result a panel of markers 
needs to be used to allow for the molecular heterogenicity of CRC. Only a few markers have been 
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identified as present in more than 40% of CRC (mutated p53, APC, KRAS)120, 121. Cell exfoliation in 
CRC and normal colonocytes is discussed in detail in section 1.3 but in summary, exfoliation from 
colorectal neoplasms is a continuous process and more frequent compared to normal colonocytes. 
In addition neoplastic cells seem to have a higher survival potential once exfoliated into the lumen 
(loss of the anoikis effect) a process discussed below in section 1.3.
Mutant KRAS was the the first DNA marker to be tested as a stool marker in 1992122 to detect CRC 
in stools from nine patients with CRC with known KRAS mutations. Following that, several studies 
have used panels of DNA markers in a screening setting to detect advanced colorectal neoplasms. 
Imperiale et al123 in 2004 used a pre-commercial panel panel of 21 mutations (PreGenPlus by Exact 
Sciences (Maynard, USA)) (3 in the K-ras gene, 10 in the APC gene, and 8 in the p53 gene) and the 
microsatellite-instability marker BAT-26 along with a marker of long DNA thought to reflect 
disordered apoptosis of cancer cells sloughed into the colonic lumen, versus gFOBT in a screening 
population. The patients were invited to provide a stool sample of up to 30g into a special container 
which was returned to the laboratory, perform a non rehydrated gFOBT(see above) and were invited 
to undergo a colonoscopy irrespective of the stool based test result. The DNA panel detected 52% v 
13% (for gFOBT) of cancers and 18% v 11% of advanced adenomas with similar specificity 
between the two tests. In 2008 Ahlquist et al124 used the same DNA panel as well as the new 3 
marker panel SDT2 (methylated vimentin, mutant KRAS, and mutant APC) in a similarly  designed 
study. The authors reported similar results with 46% v 10% for gFOBT for advanced neoplasms. In 
this study however the false positives were higher in the DNA test  (48%) compared to 21% in 
gFOBT.
At the moment stool DNA tests are not used in any screening program in the world, however the 
American Colleges of Radiology125 and Gastroenterology126 have included stool DNA testing in the 
recommended screening modalities if used every 3 years. As new markers, sampling, isolation and 
analysis technology improves DNA tests will most likely replace FOBT in the future.  
! 1.2.2.2 Structural Colonic Examinations
Endoscopy
There are two endoscopic methods to examine the colon and rectum, flexible sigmoidoscopy and 
colonoscopy. The main difference between the two is that  flexible sigmoidoscopy examines only 
part of the colon while colonoscopy examines the entire length of the large bowel. In addition 
flexible sigmoidoscopy does not require any sedation, is quicker and can be performed outside a 
designated endoscopy unit. Both procedures require the patient to receive some form of  bowel 
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preparation with most units using enemas for sigmoidoscopy and full bowel preparation (patient 
receives strong laxative the day before the procedure and follows a special dietary intake) for 
colonoscopy.
Flexible sigmoidoscopy in CRC screening
In 2010 Atkin et al127 published the results of a RCT looking at the effectiveness of once only 
flexible sigmoidoscopy as a screening tool for CRC. All patients between  55 and 64 years that were 
registered with a GP were invited to participate. The patients were excluded if they were unable to 
provide informed consent, had a history of bowel cancer or adenoma, inflammatory  bowel disease, 
life expectancy of less than 5 years or had lower gastro-intestinal endoscopy within the last 3 years. 
In addition patients were asked whether if invited they would take up screening test for CRC 
screening. Those who answered yes were randomised to the intervention arm (flexible 
sigmoidoscopy) or control group. Patients in the intervention group received one flexible 
sigmoidoscopy in their local endoscopy  unit. If adenomas were identified they  were removed and if 
patients deemed high risk were subsequently referred for full colonoscopy. The primary  outcomes 
of the study were incidence of CRC and mortality  of CRC with a median follow up of 11.2 years. In 
an intention to treat analysis they showed a 31% (hazard ration 0.69, CI 0.45-0.72) reduction in 
mortality from CRC in the intervention group and a 23% (0.77, 070-0.84) reduction in incidence of 
CRC. When correcting for self selection bias, mortality was reduced by 43% (0·57, 0·45–0·72)  and 
the incidence of CRC by 33% (0·67, 0·60–0·76) in those participating in screening. 191 persons 
needed to be screened to prevent one cancer. The main limitation of this trial was that due to the 
way patients were recruited (only those that answered yes to the question ‘would you participate in 
a screening program?’) meant that the uptake was significantly  higher than that expected if this was 
done in a population based study. Interestingly the interim report of the population based 
NORCCAP trial128, which also looked at once only flexible sigmoidoscopy in a similar age group to 
the UK trial, showed no difference in CRC incidence. It also showed a significant reduction in 
mortality from CRC (59%, hazard ratio 0.4. 95% CI 0.21-0.82). One explanation the authors gave 
was that  the study follow up period (7 years) was shorter than the time that an adenoma will take to 
turn malignant especially in view of the results of the UK trial. Two further ongoing trials are due to 
report results in the next few years129, 130. With flexible sigmoidoscopy the procedure related 
complications (bleeding, perforation) are relatively low (0.03%)127, 128. However there are 
significant differences in adenoma detection rate between endoscopists of varying experience. This, 
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along with the inability to accurately  measure the length of scope insertion makes quality  assurance 
of a screening program challenging131.
Based on the above evidence several countries are considering introducing flexible sigmoidoscopy 
into their bowel cancer screening programs including England as discussed below.
Colonoscopy
Unlike flexible sigmoidoscopy, colonoscopy requires formal bowel preparation, allows inspection 
of the entire colon and can be a diagnostic and a therapeutic modality (polypectomy, biopsy etc). 
However it  requires sedation, takes longer to perform and hence is more resource intense than 
flexible sigmoidoscopy. The higher complication rate  (0.1-0.3%)132, 133 of colonoscopy namely 
perforation 0.001% (0.002% after polypectomy) and bleeding 0.1%134 reflects its interventional 
potential. Colonoscopy remains the end point  of all screening programs throughout the world. 
Surprisingly only  a few countries have colonoscopy as the first line screening method with the 
American College of Gastroenterology recommending it as its preferred method of screening at a 
10 year interval126 beginning at the age of 50. It remains the gold standard for detection of 
significant colonic neoplasia but it still caries a significant adenoma miss rate of 20-26% for all 
adenomas with 2.6% for adenoma >1cm135, 136 due to both patient factors and quality standards of 
the examination. On the other hand a negative colonoscopy can reassure both patient and healthcare 
professionals as the risk of developing CRC following a negative test is very  low even 10 years 
later137-139. Several studies138, 140 have shown a significant reduction (53-72%) in CRC incidence as 
well as a 31% mortality  reduction from CRC. Interestingly  Baxter et al140 showed that the reduction 
in mortality was mainly  from lesions detected in the distal colon (sigmoid and rectum) and not from 
proximal colonic sites, raising the point that  these lesions could have been detected by a flexible 
sigmoidoscopy based screening program.
CT Colonography (CTC)
CTC is a radiological investigation which can image the entire colon like a colonoscopy (hence the 
term virtual colonoscopy has also been used to describe it). It involves CO2 insufflation via a small 
rectal catheter to allow better visualization of the gut. Spiral X-ray images are obtained and the 
computer software reconstructs the images into a two or three dimensional image. It does not 
require full bowel preparation but the patient has to go to a modified diet for a few days prior to the 
test. It also offers imaging of extra colonic structures at the same sitting. There are no significant 
complication rates observed in large series of CTC in a screening cohort141 with the main issue 
33
being the exposure of a healthy  patient to ionising radiation in the context of a screening program. 
This is addressed by using low radiation dose protocols of up  to 12.5mGy with most scans 
delivering about 10mGy (1 Gray= Absorption of 1 Joule of ionising energy by 1 kilogram of 
biological tissue)142. For comparison a standard CT of the abdomen and pelvis exposes the patient 
to 10mGy, equivalent to three years of natural background radiation or 100 chest X-rays.
Several large studies examined the performance of CTC as a screening method for CRC. In 2003 
1233 asymptomatic patients were recruited to a trial143 where they  received a CTC followed by 
colonoscopy  on the same day. The performance of both tests was compared. The results were 
comparable between the two tests with CTC having high sensitivity for large adenomas (94% v 
81% in colonoscopy) but lower for smaller polyps (94% v  92% for polyps up to 8mm, 88% v 92% 
for up to 6mm) and a specificity of about 96% overall for CTC. Kim et al141 compared primary 
screening using CTC in one arm and colonoscopy in the other (about 3000 patients in each arm) in 
consecutive asymptomatic patients with no randomisation. The end point of the study  was detection 
of advanced colorectal neoplasia. Patients within the CTC arm that had polyps >6mm were offered 
colonoscopy  and polypectomy while patients with more than 2 smaller polyps were offered CTC 
surveillance. This study demonstrated comparable yields of diagnosis of advanced colorectal 
neoplasia between the two arms. A further study144 in 2008 demonstrated a detection rate of 90% for 
polyps more than 10mm with a false positive rate of 14%. The main limitation of CTC lies in its 
inability to accurately detect smaller polyps as they can be difficult  to distinguish from feacal 
residue145. However studies143, 146  have shown that such polyps detected at colonoscopy have low 
risk malignant potential (<50%) with the chance of advanced histology being 1.7%. 
Conclusions
There is good evidence for gFOBT based screening programs which could improve further 
compliance with the introduction of FIT119, as only one sample will be required per patient. In 
addition flexible sigmoidoscopy once at the age of 55 has shown significantly  higher mortality 
reduction compared to gFOBT and a combination of the two might be an appealing screening 
method. There are some good candidates for alternative screening methods namely CTC with 
comparable detection rates to colonoscopy for large polyps. Colonoscopy is the gold standard 
examination of the large bowel and is the end point of most screening programs around the world. 
However it has its limitations in detecting polyps and has a significant complication rate and impact 
on healthcare resources with lower patient uptake. Stool DNA tests show promising potential and 
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will be strong candidates as sampling, isolation and analysis technology improves over the next 
years as well as the discovery of new potential markers.
The ideal screening test will be patient friendly, with minimal complications, low cost with high 
sensitivity and specificity.
  
1.2.3. Screening for colorectal cancer in the United Kingdom
England
In the late 1990s the National Screening Comittee comissioned the first colorectal cancer screening 
pilot to assess the effectiveness of screening for CRC using FOBT. This was based on evidence 
from four RCTs that demonstrated significant reduction in mortality from CRC(discussed in section 
1.2.2.). The pilot  began in 2000 in the West Midlands in England and three sites in Scotland and 
486,355 patients were offered screening. The pilot  demonstrated that the key beneficial results 
observed in the RCTs were repeated in a population based programme147. In 2003 the Department 
of Health commissioned a second round pilot into bowel cancer screening. The aim of this round 
was to evaluate key  outcomes and analyse the impact on hospital services. It was designed to build 
on the evaluation of the first round pilot. As the sensitivity of screening had already been evaluated 
in the first round, the emphasis of this pilot was shifted toward the impact of screening on resources 
and uptake by  patients. 127,746 patients aged 50-69 were invited to participate in the second pilot. 
Only 52.1% of the invitees returned a screening kit (58.4% in first round), with higher uptake rates 
in those that had previously participated in the first pilot. As before the uptake was lower in areas 
with a high proportion of people form the Indian Sub-Continent. However colonoscopy uptake had 
improved compared to the first round (82.8% v 80.5%) with no differences in uptake due to 
ethnicity or sex. Overall the sensitivity of screening was comparable to the Nottingham RCT 
results. The effect of screening on endoscopy  unit increased workload ranged from 14 to 28%, 
similar to the first round. Healthcare personnel had a positive attitude towards bowel screening 
despite the increased pressure on resources. The second pilot recommendations were in favour of 
bowel cancer screening overall with specific recommendations on maximising patient uptake, 
patient and healthcare education and ongoing evaluation of the screening programme148.
In 2006 the National Health Service Bowel Cancer Screening Program (NHSBCSP) was rolled out 
across England. Local screening centers were established within the 5 bowel screening program hub 
areas covering England. The initial target  age group was 60-69 years old with a biannual cycle of 
screening. In 2008 the screening age was extended across screening centers in England to include 
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women and men up to 75years old. This process is expected to be completed in all 58 local 
screening centers during 2013.
Patients initially received an invitation letter followed by the FOBT kit. The patients are asked to 
collect two samples from each of three separate bowel motions. They then post the kit back to their 
local screening centre for analysis. Patients receive their results within 14 days of sending in their 
kit. There are five possible results:
• Normal. No blood detected in any of the six samples. The patient will be sent another kit in 
two years time.
• Unclear. 1-4 positive samples. A letter is sent to patient with an explanation of the result along 
with a second kit to repeat the test. If the second FOBT is normal the patient is sent a third kit 
and if that is again normal the patient goes back into biannual testing. If the second or third 
FOBT is unclear or abnormal, the patient is given an appointment to see a screening nurse to 
discuss colonoscopy at the local screening centre. 
• Abnormal. 5-6 positive samples. The patient receives a letter and an appointment to see the 
screening nurse in the local centre within a week of the receipt of the letter. Patients GP is 
notified.
• Technical failure. There has been a problem in the laboratory processing the samples. A repeat 
kit is sent to the patient.
• Spoilt Kit. The kit can not be processed as it was not used correctly. The patient  is sent a 
instructions and a new kit.
Patients with an abnormal test are seen by a specialist screening nurse who assesses them for fitness 
for bowel preparation and colonoscopy. If the patients is deemed unfit for colonoscopy alternative 
colonic imaging might be offered. Colonoscopy for bowel screening is performed by  designated 
screening endoscopists in each centre. These endoscopists have been trained and passed the 
colonoscopy  driving test, to perform screening colonoscopy that meets specific procedural criteria 
to be deemed complete. About 5 in 10 screening colonoscopies are normal, with 4 in 10 
demonstrating polyps and 1 in 10 cancer. Depending on the result  of the colonoscopy the patient is 
either discharged back to the screening program (normal endoscopy) or enters endoscopic 
surveillance depending on the findings (number and size of polyps found). If CRC is detected the 
patient is referred to the local CRC MDT for further investigation and management.
In April 2011 NHSBCSP announced that it will introduce a flexible sigmoidoscopy screening pilot 
in addition to the current program. This is expected to start in 2013 in six bowel screening centers 
and will invite men and women around their 55th birthday. Later in 2011 NHSCBCSP announced 
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that the programme will be looking to replace the guaiac based FOBT to the more accurate and 
specific immunochemical FOBT over the next few years (discussed in detail in section 1.2.2.2).
Wales
Bowel screening in Wales was introduced in 2008 by Bowel Screening Wales149 (BSW). Initially 
men and women between the age of 60-69 were invited to complete FOBT as in England. The used 
kits are sent by the patient to the central screening laboratory and results sent back to patients as 
described above for England. Patients with positive results are invited for a telephone assessment 
with a specialist screening practitioner (specially trained nurse) based at  local assessment centers 
throughout Wales and are usually offered colonoscopy. One major difference between the Wales and 
England screening programs is that those patients with an unclear FOBT, they get an iFOBT instead 
of receiving a second FOBT as they do in England. The pathway for the patient in Wales following 
colonoscopy  is exactly  the same as described above for England program. Once again the quality of 
colonoscopy  is very intensely  monitored and audited. BSW have also extended their target age 
group to include those in the 70-74 years from 2010  and 50-59 years by 2012.
Scotland
As with the England and Wales programs, bowel cancer screening was introduced to Scotland 
following the two successful pilots (first pilot included three sites in Scotland) in 2007. Unlike 
England and Wales the program started with a different age group to include every patient 
registered with a GP between the age of 50-74 years. As with England and Wales the patients are 
sent a FOBT kit which they complete and send back. If the result is unclear an iFOBT is sent to the 
patient. If the result of the FOBT is positive then the patients are sent an information leaflet with 
details of their local NHS Board where they are pre-assessed for fitness to undergo colonoscopy. 
This pre-assessment can be done over the telephone or with an interview and depends on local NHS 
Board policy  and patient preferences. Once patients have their colonoscopy  their pathways are 
similar to those in England and Wales. The Scottish Bowel Screening Programme150 is monitored 
and coordinated by the National Screening Co-ordinator. 
Northern Ireland
As with the rest of the UK, NI introduced bowel cancer screening in 2010 initially to cover 
population between 60 and 69 years old and is scheduled to cover patients up to 74 years old over 
the next few years. The used kits are sent  by  the patient to the central screening laboratory  and 
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results sent back to patients as described above for England. Patients with positive results are 
invited for an assessment with a specialist screening practitioner (specially trained nurse) and are 
usually  offered colonoscopy. As with the Wales program patients with unclear first FOBT they get 
an iFOBT instead of receiving a second FOBT as they  do in England. The pathway for the patient in 
Wales following colonoscopy is exactly the same as described above for England program151.
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1.3 Cell Exfoliation in human colon
 1.3.1 Normal colonocyte mucosa
The large bowel wall consists of 4 layers (Figure 1.3): the mucosa, submucosa, muscularis propria 
and serosa. The serosa (formed by visceral peritoneum) and the muscularis propria (contains inner 
circular and longitudinal smooth muscles as well as myenteric Auerbach nerve plexi) mainly form 
the structural support for the bowel wall while the submucosa contains the Meisner nerve plexi as 
well as blood vessels. In this section we will concentrate on the mucosa which contains the 
differentiated epithelial cells.
           Figure 1.3: The layers of the human colon.
In human colon there are four types of differentiated epithelial cells. The colonocyte (columnar 
epithelial cell) is the principle cell of the mucosa, followed by the mucus secreting Goblet cells. 
Enteroendocrine cells and Paneth cells (mainly found in small intestine and ascending colon) are 
the other much less numerous cell types found in colonic mucosa. Unlike the small intestine the 
colon does not have villi (protrusions of the epithelium) but like the small bowel it  has crypts 
(shallow pockets of epithelium)152. In normal physiological circumstances the gut mucosa 
undergoes complete self renewal every 2-7 days153. This impressive co-existence of both 
proliferating and differentiated cell in the gut mucosa is driven by gastrointestinal stem cells found 
at the base of the crypts. Although the exact position of these stem cells is subject to debate it is 
generally  accepted that they are found at  the bottom of the crypts in a so called stem cell 
compartment or niche153. The remaining lower two thirds of the crypt  are occupied by proliferating 
colonocytes while the surface epithelium (luminal) and top one third of the crypt are occupied by 
differentiated cells. These stems cells do not migrate out of the crypt152. The differentiated 
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colonocytes spend a few days on the luminal surface to the mucosa where they are replaced by 
newer cells migrating from the bottom of the crypt. This constant flow of new colonocytes from the 
crypt to the mucosal surface requires an efficient mechanism of disposing the old colonocytes. This 
can be achieved in two ways and initially it was widely believed that colonocytes were simply 
removed from the luminal mucosa by exfoliation into the lumen154-157. The second way is via 
apoptosis either in situ or via the process of anoikis (apoptosis induced by loss of cell matrix 
interactions)158. In the normal colon there is dual anchorage of epithelial cells to both the basement 
membrane and to their neighbors via cell-cell adhesion mechanisms of their lateral membranes. At 
the same time the basement membrane has different distribution of various adhesion molecules at 
the base of the crypt compare to luminal surface giving it a more sticky profile the deeper into the 
crypt. Interestingly  a similar pattern is seen in the expression of the Bcl-2 and caspase family of 
proteins in the colonocyte depending to its geographical position in the mucosa, with pro apoptotic 
proteins expressed at the surface159. It  is now generally accepted that in the normal colonic 
epithelium apoptosis takes place in situ and cells are mainly removed by mucosal macrophages via 
phagocytosis and some colonocytes are exfoliated and eliminated by anoikis and disposed into the 
lumen160-163. This mechanism is almost  reversed in the neoplastic colonic epithelium which will be 
discussed in detail below.
 1.3.2 Colonic exfoliation in neoplasia
As described above in the normal colon differentiated colonocytes are believed to arise from stem 
cells found at the bottom of the crypts and migrate towards the surface where they  end their short 
lives. This has led to the “bottom-up”  theory of morphogenesis of colorectal neoplasia summarised 
below (Figure 1.4A). 
Studies of mice and human mucosa that harbor the APC mutation demonstrated that adenomas 
expanded through the process of crypt fission, where the crypt is initially bifurcated at its base 
followed by longitudinal division of the entire crypt164,165. These events are under the control of 
intestinal stem cells and adenomatous crypts do indeed arise from normal crypts165. In 2002 Wong 
et al166 examined biopsies taken at  colonoscopy of normal colonic mucosa, hyperplastic polyps and 
adenomas (hereditary colorectal cancer patients were excluded) which were then micro-dissected to 
individual crypts. The morphology of the cells, their proliferating characteristics and fission indices 
of crypts were analysed. They showed that crypts in colorectal adenomas and hyperplastic polyps 
were significantly larger than normal mucosa and at the same time crypt fission was very common 
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in polyps but very  rare in normal mucosa. There was also an upwards expansion of the proliferation 
compartment in adenomas i.e. mitoses were equally distributed along the crypt continuum. It is 
widely  believed that stem cells at the base of the crypts which are normally slow to divide and 
tethered to a niche at the base of the crypt accumulate oncogenetic mutations that result  in 
dysplastic crypts which will result in neoplastic lesions at the surface of the epithelium153, 155, 166.
However histological examinations of early adenomas have shown the presence of dysplastic cells 
at the orifice and luminal surface rather the bottom of the crypts which contradicts the “bottom up” 
theory167,168. In 2001 a different theory of cacrinogenesis was put forward by Shih et  al169 describing 
a “top-down” morphogenesis in colorectal tumours (Figure 1.4B). The molecular characteristics of 
cells isolated from both the base and the orifices of  the same crypts in adenomas were examined. 
Figure 1.4: The bottom up (A) and top-down theories of morphogenesis in colorectal tumours. 
        (www.medascape.com, accessed February 2013)
They  showed that dysplastic cell at the tops of the crypts had genetic alterations of APC and 
neoplastic associated patterns of gene expression, but at  the same time cells at the base of the same 
crypt did not have these molecular characteristics. They suggested two mechanisms through which 
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top-bottom morphogenesis takes place. Firstly  that it could be that the stem cells do not reside at  the 
bottom of the crypt but at its inter-cryptal zones and grow laterally  pushing normal cells towards the 
bottom of the crypt. A second explanation was suggested  which accepts that the stem cell does 
indeed reside at the bottom of the crypt then it  moves to the top where it  continues proliferating 
starting to replace and push normal colonocytes towards the bottom of the crypt. At the moment 
both theories are accepted with no one more dominant than the the other. It  is widely  agreed that  the 
luminal epithelium is involved very early on in the neoplastic process. 
 Colonocyte exfoliation during early stages of neoplasia is not well understood unlike that in 
established cancer where both deregulation of apoptosis170,171 and loss of cell to cell adhesion are 
associated with malignancy172-174 and suggest that tumour colonocytes end up in the colonic lumen. 
Indeed several studies have reported increased colonocyte exfoliation in colorectal cancer 
patients160, 175, 176 both in stool samples but also in the mucocellular layer. More specifically 
Ahlquist et  al 160 examined tissue samples from 20 resected colorectal cancers specimens. They 
looked at the mucocellular layer (MCL) both directly over tumour sites as well as adjacent normal 
mucosa using immunocytochemistry measuring mean cell density. This was found to be 
significantly higher 2,639/mm2 compared to adjacent mucosa 184/mm2. Interestingly they observed 
that the cells found in the MCL above tumours were not apoptotic, and were mostly colonocytes 
along with chronic inflammatory cells while those cells over normal mucosa were mostly apoptotic. 
Numerous studies have reported secondary  distal tumours177-179 in colorectal cancer patients, via re-
implantation of viable tumour cell at sites at distal distances to the tumour. Two recent studies180,181 
used a ballon device to collect  rectal mucus from patients referred to outpatients for colonic 
symptoms (change in bowel habit, rectal bleeding) and measured the DNA concentration in their 
samples. They both found significant DNA counts in patients diagnosed with malignancy compared 
with patients with normal colonic investigations (colonoscopy). Although DNA extracted from stool 
would be a useful target  for identification of biomarkers, extracting DNA of sufficient  amount and 
quality from stool remains challenging. 
The above observations, namely higher exfoliation of colonocyte in tumour, detection of viable 
colonocytes in the MCL over tumours, distal metastasis of tumours within the colon and DNA in 
the stool and rectal mucus, suggest  accumulation of DNA from the tumours towards the rectum 
along the MCL which forms the basis of our hypothesis.  
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2. Hypothesis
The hypothesis is that in patients with colorectal cancer, rectal mucus may contain DNA derived 
from colonic tumours. These tumours may exfoliate cells which pass distally to the rectum. 
Sampling of mucus in the rectum may  permit assessment of DNA derived from proximal tumour 
cells. It is speculated that quantitative or qualitative assessment of DNA in rectal mucus may permit 
an improved method of CRC screening.
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3. Aims
1. Detection of DNA in mucus from colon
• To establish whether it is possible to perform quantitative measurements of DNA in mucus
       samples taken from human surgical colonic specimens in a repeatable and reproducible method
• To establish an appropriate buffer solution to store the mucus collection device following
        sampling of human colonic mucus and should it be stored at room temperature or refrigerated
2. To establish which collection material will yield the highest DNA content from colonic mucus.
3. Is there a gradient of DNA concentration in colonic mucus from the tumour site proximally or
distally?
 • To establish the amount of DNA at tumour sites and set distances proximally and distally from
       the tumour site and to identify if there is a pattern or not.
4. Can we use DNA isolated from rectal mucus to detect colorectal cancer?
 •  To identify if there is a significant difference in the amount of DNA extracted from sampled 
rectal mucus between patients with neoplasia and those without. 
• To identify if a patient  has CRC by using a three marker methylation panel assay on DNA 
isolated from rectal mucus in symptomatic patients referred to a colorectal clinic.
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4. Detection of DNA in mucus from colon surgical specimens
In order to test our hypothesis we first needed to prove that it  was possible to collect, safely store 
and accurately measure the DNA content of colonic mucus. This chapter describes the experiments 
that  address these issues.
4.1 Objectives
i. To establish whether it was possible to perform quantitative measurements of DNA in a 
mucus sample taken from human surgical colonic specimens in a repeatable and 
reproducible method.
ii.To establish an appropriate buffer solution in which to store the mucus collection device 
following sampling of human colonic mucus.
iii. To determine the optimum temperature at which the samples should be stored.
4.2 Methodology
 4.2.1  Is it possible to perform quantitative measurements of DNA in mucus samples 
  taken from human surgical colonic specimens in a repeatable and reproducible 
  method ?
Preparation of collecting device
Glove
A piece of Encore® under-glove (Ansell Healthcare Ltd) was fashioned by cutting the glove into a 
1x4cm rectangle. The pieces were then placed in a sterile pot for storage. This type of glove is made 
of natural rubber latex.
 
Collection of surgical specimens and sampling of colonic mucus
Patients who were undergoing bowel resection as part of their bowel cancer treatment plan were 
consented as described in the research ethics committee approval form (ref: 11/NE/088) (appendix 
I). The patients received no bowel preparation prior to surgery. The operation proceeded as normal 
and once the bowel specimen had been removed and operation completed the specimen was sent to 
pathology as per normal clinical practice. On arrival of the resected bowel at  the pathology cut-up 
room, the candidate was contacted and asked to attend.
The pathologists opened the colon in a fashion that did not undermine the clinical pathological 
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staging of the colonic specimen. The colon was opened starting from the distal resection margin. 
The bowel wall was cut longitudinally following the taenia coli reaching as close to the tumour site 
as possible. This procedure was followed from the proximal resection margin towards the tumour. 
The specimen was opened without washing the lumen of any stool as such a manoeuvre would 
flush out mucus and affect the results of the measurements. The colonic specimen was placed on a 
clean bench.
An area of uncontaminated (no stool) mucosa was identified and its distance from the tumour site 
recorded (20cm proximal to tumour). A piece of glove with a surface area of 4cm2 was applied to 
the sampling area for a total of ten seconds. To ensure that the same force/pressure would be applied 
during sampling, a fixed weight (20g) was applied on top  of the piece of glove (Figure 4.1). Care 
was taken to avoid any  scraping movements that would result in sampling mucosa instead of 
mucus. Five measurements were taken at this site, circumferentially, using the same collection 
device (glove) as described below and the same was repeated at similar distance for the tumour in a 
different colonic surgical specimen. 
Figure 4.1: Diagram to demonstrate sampling of colonic mucus using a piece of glove (green) 
            using a fixed weight (brown) of 20g at a set distance from tumour (black).
Following mucus sampling, the piece of glove was placed in a 15ml Falcon tube 
(BD Biosciences, USA) containing 3ml of Cell Lysis Solution (Cat No 158908, Qiagen GmbH, 
Germany). Care was taken to ensure that the entire surface of the glove/foam was covered with cell 
lysis buffer. The samples were then stored at room temperature and transferred to the laboratory.
Extraction of DNA from colonic mucus samples
Principles of method
• Colonocytes in the mucus sample were lysed to release their DNA content. The lysis solution 
broke down the cell membrane and the nuclear membrane, releasing the cytoplasmic and nuclear 
contents into solution.
• RNAse was added to lyse all RNA that had been released from the cell lysis, leaving only DNA 
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and proteins in solution.
• Next the proteins were removed from the solution by adding protein precipitation solution 
containing ammonium acetate that precipitated the protein into a tight pellet.
• The DNA was in solution and by  using isopropanol and glycogen it was precipitated by 
centrifugation, and after washing the pellet with ethanol it was rehydrated using DNA hydration 
solution.
Protocol (Modified Gentra Puregene Buccal Cell Kit protocol, Qiagen GmbH, Germany)
• Cell lysis was achieved by incubating the 15ml Falcon tubes with the collecting device immersed 
in the 3ml of cell lysis buffer, at 66 oC for one hour.
• Samples were kept  at room temperature for 30 minutes to cool down and each sample was 
vortexed (Vortex Genie-2, Scientific Industries Inc, USA) at high speed for 20 seconds to 
homogenise the solution.
• 300µL of the solution was pippetted into a 1.5ml sterile micro-centrifuge tube (Eppendorf 
Lobind®, Germany).
• To ensure RNA free DNA 1.5µL of RNase A solution (Cat No 158924, Qiagen GmbH, Germany) 
was added and the micro-centrifuge tubes incubated for 15min at 37 oC. Samples were then 
cooled down by placing on ice for one minute.
• 100µL of protein precipitation solution (Cat No 158912, Qiagen GmbH, Germany) was added to 
separate proteins from DNA and vortexed at  high speed for 20 seconds. Samples were then 
incubated in ice for 5 minutes and then centrifuged for 3 minutes at  16,000g (Eppendorf 
Centrifuge 5415C, Germany). 
• The resultant supernatant contained DNA in solution and a tight precipitated protein pellet. 
• The supernatant was then added to a clean 1.5ml micro-centrifuge tube containing 300µL of 
isopropanol and 0.5µL of Glycogen (Cat No 158930, Qiagen GmbH, Germany). 
• The samples were mixed gently by inverting 50 times  and they were then centrifuged for 
5minutes at 16,000g to form a DNA pellet. 
• The supernatant was carefully discarded, taking care the DNA pellet was not dislodged
• The DNA pellet was verified visually.
• 300µL of 70% ethanol was added to wash the DNA pellet and samples were centrifuged for 
1minute at 16,000g.
• The supernatant was drained again taking care the DNA pellet was not dislodged and samples 
were allowed to air dry for 15 minutes.
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• 20µL of DNA Hydration solution (Cat No 158914, Qiagen GmbH, Germany) was added and the 
samples vortexed for 5 seconds at medium speed and incubated at 65 oC for 1hour to hydrate the 
DNA.
• The samples were then stored overnight with gentle shaking using a 3D Rocking Platform STR9 
(Stuart Scientific, UK).
• Samples were centrifuged briefly (Capsulefuge PMC-100 Tomy Teoh, USA) for 10seconds the 
next morning before measuring their DNA content using a spectrophotometer.
• The ND1000 Spectrophotometer (Nanodrop® Tech Inc, USA) was used to measure the DNA 
content in each sample. The Nanodrop® was cleaned before and after every sample was loaded 
with sterile water. The machine was calibrated by loading 1µL of ddH2O followed by  1µL of 
DNA hydration solution as a blank measurement. 1µL of each sample was loaded on the 
Nanodrop® and its DNA concentration (ng/µL)  and A260/280 ratio was recorded. Values <10ng/
µL and/or those with A260/280 ration outside 1.60-2.1 or with a spectrum graph with not a single 
peak were considered not to contain any DNA .
 4.2.2  To establish an appropriate buffer solution to store mucus collection device 
  following sampling of human colonic mucus, and whether it should be stored at 
  room temperature or refrigerated. 
Four buffers (described below) were studied for their properties as solvents in which to store DNA 
derived from rectal mucus. Storage temperature, easy availability and high DNA yield were 
considerations in the choice of buffer.
Buffers 
Cell Lysis Buffer (Cat No 158908, Qiagen GmbH, Germany)
This buffer has been used in the preservation of mucus samples from the rectum in published 
studies180, 181.
ASL Stool Lysis Buffer (Cat No 19082, Qiagen GmbH, Germany)
This buffer (also known as ASL Stool Wash Buffer) was chosen as it has been used in studies 
looking for DNA methylation markers in human stool samples183.
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RNALater Buffer (Cat No 76106, Qiagen GmbH, Germany)
A commonly  used buffer, but as it  is designed to preserve mainly RNA in preference to DNA 
therefore would be expected to act as a negative (or near negative) control.
Phosphate Buffered Solution (PBS)
PBS was chosen  because is a commonly used biological buffer/solvent but it  does not feature as a 
nucleic acid preservative or solvent and therefore was chosen as a negative control.
Collection of surgical specimens and sampling of colonic mucus
The surgical specimen was collected and cut up by the pathologist as described in section 4.2.1.
An uncontaminated (stool free) area of the bowel with no tumour or polyps was identified. Using a 
Colonic Mucus
Colonic Mucosa
100μL of mucus 
sampled using a 
pipette
Metallic Ruler was drawn for 5cm 
Figure 4.2: Diagram to demonstrate how a fixed volume of mucus was sampled from a surgical 
         colonic specimen. 
metallic ruler the mucus was scrapped gently over a distance of 5cm (Figure 4.2). Using a pipette 
100µL of mucus was placed into four 15ml Falcon tubes (BD Biosciences, USA) each containing 
3ml of one of the above four buffers. The Falcon tubes were then vortexed gently for 10 seconds to 
homogenise the solutions. 1.5ml from each solution was then transferred on a clean 15ml Falcon 
tube. The tubes were either kept in room temperature or stored in 4 oC. The DNA concentration of 
the 8 solutions was measured using the following protocol at 48hrs, 1 week, 2 weeks and 4 weeks 
after sampling.
Measurement of DNA concentration
Principle of methods
• The four main principles of the protocols are those described in 4.2.1 but here we have assumed 
our solutions to be tissue fluid.
• 5 measurements from each buffer solution were taken at every time point.
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Protocol (Modified Gentra Puregene blood Kit body fluid protocol, Qiagen Gmbh, Germany)
• 50µL from each solution were added to a 1.5ml sterile micro-centrifuge tube (Eppendorf Lobind®, 
Germany) containing 250µL Cell Lysis Solution (Cat No 158908, Qiagen GmbH, Germany) and 
incubated for 1 hour in 66 oC.
• To ensure RNA free DNA, 1.5µL of RNase A solution (Cat No 158924, Qiagen GmbH, Germany) 
was added and the micro-centrifuge tubes incubated for 15 minutes at 37 oC. 
• Samples were cooled by placing on ice for one minute.
• 100µL of protein precipitation solution (Cat No 158912, Qiagen GmbH, Germany) was added to 
separate proteins from DNA and vortexed at high speed for 20 seconds and incubated in ice for 5 
minutes. 
• Samples were centrifuged for 3 minutes at 16,000g (Eppendorf Centrifuge 5415C, Germany). 
• The supernatant containing DNA was added in a clean 1.5ml micro-centrifuge tube containing 
300µL of isopropanol and 0.5µL of Glycogen (Cat No 158930, Qiagen GmbH, Germany) and 
mixed gently by inverting 50 times.
• Samples were centrifuged for 5 minutes at 16,000g to form a DNA pellet.
• The supernatant was carefully discarded, taking care the DNA pellet was not dislodged. The 
DNA pellet was verified visually.
• 300µL of 70% ethanol was added to wash the DNA pellet and samples were centrifuged for 1 
minute at 16,000g.
• The supernatant was drained again taking care the DNA pellet was not dislodged and samples 
were allowed to air dry for 15 minutes.
• 20µL of DNA Hydration solution (Cat No 158914, Qiagen GmbH, Germany) was added and the 
samples, vortexed for 5 seconds at medium speed and incubated at  65 oC for 1 hour to hydrate the 
DNA.
• The samples were stored overnight with gentle shaking using a 3D Rocking Platform STR9 
(Stuart Scientific, UK).
• The following morning, samples were centrifuged briefly (Capsulefuge PMC-100 Tomy Teoh, 
USA) for 10 seconds before measuring their DNA content using a spectrophotometer.
• The ND1000 Spectrophotometer (Nanodrop® Tech Inc, USA) was used to measure the DNA 
content in each sample as described in section 4.2.1.
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4.3 Results
 4.3.1 Is it possible to perform quantitative measurements of DNA in a mucus sample 
  taken from human surgical colonic specimens in a repeatable and reproducible 
  method ?
Five different measurements using a 4cm2 piece of glove as described above were taken from the 
same distance proximal to tumour (20cm) and DNA was isolated and measured as described in 
section 4.2.1. Table 4.1 summarises the results of those measurements. These results are expressed 
in ng/µL, referring to DNA isolated per colonic mucus sample in 20µL of DNA Hydration solution 
which was added to the isolated DNA pellet as described in sections 4.2.1 and 4.2.2.
The average DNA concentration was 37.7 ng/µL (95% CI 36.81-37.77, Standard deviation 0.77). 
The experiment was repeated at a similar distance (20cm) in another colon (Table 4.1) with a mean 
concentration of 25.3 ng/µL (95% CI 24.3-26.3, Standard deviation 0.81).
Individual measurements
(ng/µL) Mean Median
Std. 
Deviation
Std. 
Error
Confidence 
Interval
Colon 1 38.30 36.70 37.90 37.30 38.60 37.76 37.90 0.767 0.34 36.81 38.71
Colon 2 25.40 24.30 26.40 24.80 25.70 25.32 25.40 0.811 0.36 24.31 26.32
Table 4.1: Individual measurements of DNA content of colonic mucus at the same distance within 
      two different surgical colonic specimen.
 4.3.2  To establish an appropriate buffer solution in which to store mucus collection 
  device  and the optimum storage temperature.
Only the samples stored in cell lysis solution had significant amounts of DNA, as shown in table 
4.2 below. DNA concentrations <10ng/µL and/or those with A260/280 ratio outside 1.60-2.1 or with 
a spectrum graph without a single peak were considered not to contain any DNA. This is due to 
potential absorption at these wavelengths by fragments of nucleic acids and proteins. DNA yield of 
cell lysis solution increases from 34.8 ng/µL to 40.25 ng/µL over 4 weeks when stored at room 
temperature (figure 4.3a) and from 34.9 ng/µL to 40.3 ng/µL at 4oC (figure 4.3b). The datasets for 
this experiment were tested using SPSS V19 (IBM Inc, USA) to assess if they were normally 
distributed. Shapiro-Wilk test was used as our sample size is small and p >0.05 in all groups and 
hence we confirmed that our data are normally distributed.
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Cell Lysis 
Buffer 
Stool Lysis 
Buffer
RNALater
PBS
Room Temperature
Mean
4 degrees
Mean
<48 hrs 1 wk 2 wks 4 wks <48 hrs 1 wk 2 wks 4 wks
34.80 38.78 40.22 40.24 34.9 34.90 37.90 39.16 40.30 38.70
4.50 6.84 7.56 8.04 6.70 5.66 8.22 8.14 8.94 7.70
4.86 7.88 7.84 8.18 7.20 7.00 7.86 8.12 8.50 7.90
8.44 7.56 7.98 7.82 7.90 8.28 8.60 9.20 8.28 8.60
Table 4.2: Mean DNA yield in ng/µL. 
To ensure appropriate statistical tests were used in the analysis of these data, the homogeneity of 
variance was also checked and found to be >0.05. Hence both assumptions (normal distribution and 
homogenous variance) were met, the use of parametric statistical tests for analysis was appropriate.  
N Mean
Std. 
Deviation
Std. 
Error
95% Confidence 
Interval for Mean Min Max
Test of 
Homog.
of VarianceLower Upper
<48 
Hours
4C 5 34.9 3.88523 1.73753 30.0759 39.7241 30.10 39.30
0.624RT 5 34.8 3.46338 1.54887 30.4996 39.1004 30.60 38.60
Total 10 34.85 3.47027 1.09740 32.3675 37.3325 30.10 39.30
week1
4C 5 37.9 2.50300 1.11937 34.7921 41.0079 34.30 40.40
0.762RT 5 38.78 2.38160 1.06508 35.8229 41.7371 35.30 41.70
Total 10 38.34 2.34956 0.74300 36.6592 40.0208 34.30 41.70
week2
4C 5 39.16 3.21139 1.43618 35.1725 43.1475 35.70 43.60
0.897RT 5 40.22 3.04828 1.36323 36.4351 44.0049 36.40 43.80
Total 10 39.69 3.00424 0.95002 37.5409 41.8391 35.70 43.80
week4
4C 5 40.3 2.52190 1.12783 37.1686 43.4314 37.30 44.30
0.393RT 5 40.28 3.09225 1.38290 36.4405 44.1195 37.40 44.50
Total 10 40.29 2.66018 0.84122 38.3870 42.1930 37.30 44.50
Table 4.3: Descriptive statistics.
A repeated measurement ANOVA was performed. The data was checked to assume that the 
sphericity-assumption was not violated (Mauchly’s Test of sphericity) and the approximate Chi-
Square value (8.394 p=0.158 for room temperature, 2.980, p=0.719 for refrigerated group) 
confirmed that the sphericity assumption was not violated.
In the room temperature group  there was no significant difference in DNA concentration over time 
(F(3,12)=2.36 p=0.123). Post Hoc Bonferroni correction in the refrigerated group showed no 
significant difference between the mean DNA concentration at the different time points despite the 
52
repeated measures ANOVA (F(3,12)=4.589, p=0.023) result.
Figure 4.4 summarises the mean DNA concentration over time when the cell lysis solution is stored 
at room temperature (blue line) or at 40C (green line). An independent T-Test (SPSS v19, IBM Inc 
USA) confirmed that there was no significant difference (t(38)=0.396 p=0.694) between the mean 
DNA concentration in solutions stored at room temperature and 40C.
Figure 4.3a: Cell Lysis Buffer stored at 40C. Means are expressed in ng/µL within one standard 
             deviation.
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Figure 4.3b: Cell Lysis Buffer stored at Room Temperature. Means are expressed in ng/µL.
Figure 4.4: Cell Lysis Buffer mean DNA concentration in ng/µL over time stored in room 
           temperature (blue line) and in 40C (green line).
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4.4 Discussion
The results of the first experiment (sections 4.2.1 and 4.3.1) show that it is possible to collect and 
accurately measure the DNA content of colonic mucus using a 4cm2 piece of latex glove. In 
addition we took repeated measurements at a specific distance (20cm) within the colonic specimens 
and got consistent DNA counts indicating that DNA amount in the colonic mucosa is uniformly 
distributed around the circumference of the colon. When we repeated the experiment in a second 
colon we were able to reproduce our results. These observations are of great relevance to the 
experiments described later in this thesis especially in chapter 6 where we measured the DNA 
content of colonic mucus at set distances proximally and distally to colorectal tumour sites. 
In the second experiment (sections 4.2.2. and 4.3.2) we have demonstrated that the best buffer 
solution to store the device used to collect mucus from the colon was cell lysis buffer. We chose to 
use a piece of glove as our device in this experiment because a latex based membrane device had 
been previously used to collect rectal mucus in previous studies180,181.  The results of this experiment 
showed a clear advantage in storing the device in cell lysis buffer compared to the other three 
buffers. The need to immerse the collecting device into a buffer is two fold:
• This maximises the yield of DNA per device, as it allows an increased surface area of 
mucus and therefore colonocytes to come into contact with the buffer solution increasing 
the number of cells lysed compared to simply scrapping the mucus drops off the device.
• In addition as described in section 4.2 cell lysis buffer does not interact with the materials of 
the device.  It  is unclear whether glove is the optimum material to collect colonic mucus but 
this question is addressed in Chapter 5.
The DNA yield from collection device placed in cell lysis buffer was stable over a period of up to 1 
month. In addition the storage temperature does not affect DNA yield. These two observation have 
significant implications for experiments described later in this thesis especially Chapter 7 where we 
sampled rectal mucus from symptomatic patients and had to store the samples for up  to three weeks 
before analysis.
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5. What is the best material to collect colonic mucus to assess DNA?
 
In the previous chapter we demonstrated that it is possible to take repeatable and accurate 
measurements of the DNA content of human colonic mucus. Here we will establish which 
collection material is best suited to this.
! 5.1  Objective
• To establish which collection material will yield the highest DNA content from colonic 
mucus. 
 5.2  Methodology
Three collecting devices made out of different materials will be compared:
• Cytology  brush from the Gentra Puregene Buccal Cell Kit  (Cat No 158867, Qiagen GmbH, 
Germany) was chosen as a positive control method of collecting DNA from colonic mucus as 
it is designed to collect saliva and buccal cells.
• A piece of glove was chosen to try  and simulate in our model a latex membrane device that 
had been successfully used  to collect rectal mucus in a published studies180, 181. 
• A polyethylene foam that  has been CE marked in the EU and has been declared safe by the 
FDA in the USA for accidental ingestion was chosen as a possible alternative material to 
collect mucus from the rectum.
Preparation of collecting devices
A piece of Encore® under-glove (Ansell Healthcare Ltd) was fashioned by cutting the glove into a 
1x4cm rectangle using aseptic technique to ensure no DNA decontamination. The pieces were then 
placed in a sterile pot for storage.
The foam sheet (40x20x5cm) provided by the manufacturer (Cat No FT-40P, Foam Techniques Ltd, 
UK) was cleaned with alcohol and allowed to air dry overnight. The sheet was trimmed by 0.5cm 
from each surface to ensure no DNA contamination had occurred from handling the foam. The 
inside (core) foam was then cut up into 1x4x0.5cm pieces and placed in a sterile pot. Five 
1x4x0.5cm pieces of foam were randomly  chosen and their surface DNA content was checked using 
the protocol described in section 4.2.1. No DNA was detected.
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Collection of surgical specimens and sampling of colonic mucus
Twenty five surgical colonic specimens were collected and cut open as described in section 4.2.1. 
No oral bowel preparation was used prior to resections. For left sided colonic resections an enema 
was given in the morning of the operation.
Each colon was opened, an area of uncontaminated (no stool) mucosa was identified and its 
distance from the tumour site was recorded. A piece of glove or foam was applied to the sampling 
area for a total of ten seconds. To ensure that the same force/pressure would be applied during 
sampling, a fixed weight (20g) was applied on top of the collecting device (Figure 5.1). Care was 
taken to avoid any scraping movements that would result in sampling mucosa instead of mucus. 
Brush sampling was done by twisting the brush 720o and taking care not to drag the brush along the 
colon, to minimise sampling mucosa instead of mucus.
20g
X cm
Figure 5.1: Diagram to demonstrate sampling of colonic mucus using a piece of glove (green) 
 using a fixed weight (brown) of 20g at a set distance from tumour (black). Cross sectional
 diagram of colon at distance Xcm from tumour showing circumferential sampling of colonic
 mucus using the three different devices (glove, foam and brush)
Extraction of DNA from colonic mucus samples
Principles of method
• As described in section 4.2.1
DNA extraction was performed following the protocol described in section 4.2.1, thus providing 
DNA for early quantification and avoiding the need for storage.
57
Glove
Foam
Brush
5.3 Results
As shown in table 5.1, 118 colonic mucus samples using foam, 117 using glove and 114 using 
cytology brush were made using 25 colonic resection specimens. The mucus DNA content was 
measured as described in section 5.2. These results are expressed in ng/µL, referring to DNA 
isolated per colonic mucus sample in 20µL of DNA hydration solution which was added to the 
isolated DNA pellet as described in sections 4.2.1 and 4.2.2. The mean DNA concentration (figure 
5.2) using:
• cytology brush was 236.2 ng/µL (95% CI 187.1-285.4) 
• foam was 179.7 ng/µL (95% CI 113.3-246.1) 
• glove  was 87.7 ng/µL (95% CI 68.1-107.4).
The data were analysed using SPSS v19 (IBM  Inc, USA) to test  for normality  (Kolmogorov-
Smirnov test). DNA concentration was non-normally distributed D(120)=0.323 p=0.0001 in foam, 
in glove D(118)=0.238 p=0.0001 and in brush groups D(114)=0.219 p=0.0001. 
We have therefore used non parametric tests to analyze and report these data. A Kruskal-Wallis test 
was used to compare the median DNA yield between the three groups. Median DNA yield was 
significantly different between the three different modalities used to sample colonic mucus H(2)
=54.1 p=0.0001. A Mann-Whitney  test was used as post hoc analysis to follow the Kruskal-Wallis 
test result above. A Bonferroni correction was used and therefore results are reported to a 0.0167 
level of significance. 
The median DNA concentration in the glove group (Mdn=48.5 ng/µL, IQR=75.4) was significantly 
lower than that in the foam group (Mdn=90.25 ng/µL, IQR=148.8) Mann-Whitney U= 4830, 
z=-4.237 p=0.0001 and in the brush group (Mdn=142.7 ng/µL, IQR=195.2) Mann-Whitney 
U=3060, z=-7.173 p=0.0001. In addition the median DNA concentration in the brush group
(Mdn=142.7 ng/µL, IQR=195.2) was significantly higher than in the foam group  (Mdn=90.25 ng/
µL, IQR=148.8) Mann-Whitney  U= 5047.5, z=-3.463 p=0.001. Results are summarised in figure 
5.2a and b.
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GLOVE N=117 Mean SD 95% CI Median IQR
10-15cm 
Distal to Tumour 21 55.00 33.37 39.81 70.19 49.50 50.75
5-10cm 
Distal to Tumour 19 65.73 34.39 49.16 82.31 48.60 61.30
Tumour site 25 231.67 152.52 170.07 293.28 163.15 180.97
5-10cm 
Proximal to Tumour 10 52.17 28.07 32.09 72.25 35.50 50.38
10-20cm 
Proximal to Tumour 18 44.43 28.38 30.31 58.54 38.10 31.00
20-40cm
Proximal to Tumour 24 25.12 20.68 20.68 29.56 24.90 10.05
FOAM N=118 Mean SD 95% CI Median IQR
10-15cm 
Distal to Tumour 22 100.76 61.52 73.48 128.04 95.75 67.57
5-10cm 
Distal to Tumour 19 133.16 91.77 88.92 177.39 86.40 146.80
Tumour site 25 500.04 681.30 230.53 769.55 262.30 289.70
5-10cm 
Proximal to Tumour 10 102.64 64.32 56.63 148.65 114.00 112.00
10-20cm 
Proximal to Tumour 18 72.52 39.71 52.76 92.26 76.35 64.22
20-40cm
Proximal to Tumour 24 40.95 19.50 32.72 49.19 39.50 22.98
BRUSH N=114 Mean SD 95% CI Median IQR
10-15cm 
Distal to Tumour 20 136.83 83.99 97.52 176.13 135.50 67.05
5-10cm 
Distal to Tumour 18 187.68 118.17 128.92 246.45 200.50 178.95
Tumour site 25 575.34 347.46 437.89 712.79 523.00 614.30
5-10cm 
Proximal to Tumour 10 194.00 87.80 131.19 256.81 194.35 140.63
10-20cm 
Proximal to Tumour 17 110.58 61.56 78.93 142.23 92.10 65.05
20-40cm
Proximal to Tumour 22 66.53 37.57 49.87 83.19 58.00 51.95
Table 5.1: DNA counts (ng/µL) per modality  used at different sites with the colon in relation to 
      tumour.
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Figure 5.2a: Mean of DNA concentration in colonic mucus collected with Glove v. Foam v. Brush. 
Figure 5.2b:Median of DNA concentration in colonic mucus collected with Glove v. Foam v. Brush
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Since DNA counts are significantly higher at the tumour site compared to non tumour sites as later 
described in chapter 6 below, we have repeated the analysis by excluding the measurements taken 
from tumour sites. Ninety three (93) colonic mucus samples using foam, 92 using glove and 87 with 
brush were made. The mean DNA concentration using foam was 86.7 ng/µL (95% CI 73.0-100.4), 
47.1 ng/µL (95% CI 40.7-53.4) with glove and 131.0 ng/µL (95% CI 111.4-150.6) with brush 
(Figure 5.3). The data in all groups were analysed for normality as described above. All data were 
non-normally distributed (foam D(93)=0.157, p=0.0001 glove D(92)=0.178, p=0.0001, brush D(87)
=0.135, p=0.001). 
A Kruskal-Wallis test was used to compare the median DNA yield between the three groups. 
Median DNA concentration was significantly  different between the three different modalities used 
to sample colonic mucus at sites with no tumour H(2)=66.53 p=0.0001. Mann-Whitney test was 
used as post hoc analysis to follow up the Kruskal-Wallis test  result  above. A Bonferroni correction 
was used and therefore results are reported to a 0.0167 level of significance. 
The median DNA concentration in the glove group  (Mdn=35.7 ng/µL, IQR=40.17) was 
significantly lower than that in both the foam group (Mdn=60.80 ng/µL, IQR=72.4) Mann-Whitney 
U= 2476.5, z=-4.947 p=0.0001 and in the brush group  (Mdn=102.0 ng/µL, IQR=117) Mann-
Whitney U= 1279.5, z=-7.857 p=0.0001. In addition brush median DNA concentration (Mdn=102.0 
ng/µL, IQR=117) was significantly higher than in the foam group  (Mdn=60.80 ng/µL, IQR=72.4) 
Mann-Whitney U= 2739, z=-3.740 p=0.0001.
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Figure 5.3a:  Mean DNA concentration in ng/µL, excluding measurements taken from tumour sites.
Figure 5.3b: Median DNA concentration in ng/µL, excluding measurements taken from tumour 
           sites.
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P<0.0167
5.4  Discussion
  In this chapter we aimed to establish the best material for collecting DNA from mucus in human 
colons. The ideal material would allow collection and also release of DNA to be analysed for the 
presence of biomarkers (chapter 7). A cytology brush was used as a positive control as it has been 
specifically designed to collect cells and DNA from buccal mucosa and is in clinical practice 
throughout the world. The obvious solution would be to use these brushes to sample rectal mucus 
from patients. Unfortunately this would not be practical for several reasons. Firstly cytology 
brushes have sharp  ends and their use during proctoscopy could result  in rectal trauma. Secondly 
our target DNA has been exfoliated from tumour colonocytes in sites proximal to the rectum. 
Cytology  brushes will also collect colonocytes from the mucosa along with some DNA from the 
overlying mucus. As a result the DNA isolated will be mainly  from rectal colonocytes instead of 
mucus DNA that has been exfoliated from tumour sites and has accumulated along the mucocellular 
layer of the colon in the rectum as described in chapter 8. 
Glove was chosen as a material as it had been already successfully used in clinical studies180, 181 to 
collect rectal mucus DNA. We opted for a sterile latex glove to ensure that there was no 
environmental DNA contamination. 
A polyethylene foam was also chosen as it is a material that it can be fashioned to an atraumatic 
device that can be used during proctoscopy. We ensured that the pieces of foam used had no DNA 
contamination as described in section 5.2. Furthermore this specific foam material has been 
approved by  FDA in USA to be safe for accidental ingestion by  children and given a CE mark in the 
EEA.
As described in detail in section 5.3 our data in the three groups (glove, foam and brush) were not 
normally distributed and therefore non- parametric statistical tests were used to analyse our results. 
A reason for this is that  samples were collected from 25 different human colonic specimens. As 
described in section 1.3 there is high variability  in the exfoliation rate of colonocytes between 
individuals and also between different tumour types. In addition exfoliation of colonocytes is 
affected by diet and physical activity hence there is variability  of the colonocyte exfoliation rate 
within the same colon from one day to another.
As expected the cytology brush yielded significantly higher amounts of DNA than either foam  or 
glove devices. This is because the cytology brush has been designed to collect mainly mucosal cells 
and some mucus over the mucosa mainly by its ability  to detach cells and mucus by friction. As 
described in section 5.2 the brush was rotated over the mucocellular layer of the colon to achieve 
maximum friction and to act as a positive control. 
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On the other hand both the glove and foam devices were applied in such way as to minimise friction 
between the device and the mucocellular layer of the colon and to maximise collection of mucus 
rather than the local mucosal colonocytes. This was achieved by vertical pressure with each device 
over the mucocellular layer of the colon avoiding any lateral movement. This reflects the future use 
of the material to fashion a clinically applicable device that will collect mucus that has travelled 
along the mucocellular layer of the colon from proximal sites (Chapter 6 and 7).
As predicted both glove and foam yielded significantly lower amounts of DNA compared to the 
positive control. Interestingly foam significantly  outperformed the glove device by yielding double 
the DNA amount compared to glove. One explanation could be that because foam has a rougher 
surface it was able to exert higher friction and as a result picked up some mucosal cells in addition 
to the overlying mucus. In addition although both glove and foam pieces were 4x1cm rectangles the 
effective  surface area (the part of the device in actual contact with colonic tissue) of the foam is 
larger than the that of the of the glove (flat smooth surface of the glove compared to the rough and 
irregular surface of the foam). This also allows more of the foam piece to be in contact with the cell 
lysis buffer resulting in more colonocytes coming into contact with the buffer compared to the 
glove device and hence more DNA released into the buffer during storage of the collecting devices 
in cell lysis buffer. 
However if we look closely  at the performance of the brush at  distances very proximal to tumour 
where there is minimal DNA from the tumour as described in chapter 6, the DNA yielded by the 
glove is 42% of that yielded by the brush at the same distance. If we then compare this at the 
tumour site (potential maximum DNA yield) the glove yielded only 34% of the brush yield. This 
suggests that our initial assumption that  the brush’s high performance is due to its ability  to pick up 
colonocytes directly from the underlying mucosa (not mucus) might not be true after all. The glove 
device exerts minimal friction to the mucosa and mainly picks up mucus while the brush due to its 
higher effective surface area (a cytology brush has many little hair like filaments) is able to pick up 
more mucus than the glove and that may  be why it is outperforming the other two devices. Ideally 
we could repeat the experiment by using a brush that has a surface area of 4cm2 (= glove) to be able 
to compare like for like, but that would be extremely  difficult to manufacture due to time and 
financial constrain.
We then compared the performance of glove and foam to that of the brush at each distance (table 
5.2). The ratio of both glove or foam to brush is not similar at every distance as expected if the 
ability  of each material to yield maximum DNA was solely reliant on its friction effect onto the 
mucosa.  
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Distance N=118 Median Glove Median Foam
10-15cm 
Distal to Tumour 22 0.36 0.71
5-10cm 
Distal to Tumour 19 0.24 0.43
Tumour site 25 0.32 0.50
5-10cm 
Proximal to Tumour 10 0.18 0.58
10-20cm 
Proximal to Tumour 18 0.47 0.83
20-40cm
Proximal to Tumour 24 0.42 0.68
Table 5.2: DNA yield expressed as median DNA collected using glove or foam over DNA collected 
       using brush at the same distance. 
Our hypothesis states that it is possible to detect DNA from proximal sites in the colon by sampling 
rectal mucus in patients with colorectal cancer. As a result we repeated the analysis of the results by 
excluding measurements taken directly over tumour sites to try and simulate the future clinical 
application of such devices. Interestingly the results of the second analysis (excluding tumour sites) 
showed much lower yields in every  category  (brush, glove and foam) although relative differences 
remained when comparing the three devices. The lower DNA yield can be explained by the 
previously  described high exfoliation rates seen in colorectal tumours (see section 1.3) and also due 
to the sharp  decline in DNA amounts seen in samples taken within short distances from tumours 
which is described in detail in chapter 6. It  is interesting that when all measurements were included 
foam yielded almost double the amount of DNA compared to glove, an observation which did not 
change when tumour sites were excluded. In addition foam yielded about 40% less DNA compared 
to brush in both analyses. 
In conclusion, the brush, although initially used as a positive control, could indeed be the best 
material to collect mucus but its advantage could be simply due to its larger surface area compared 
to the other two devices. In addition it will be challenging to fashion an atraumatic cytology brush 
that can be inserted safely into the rectum. One suggestion to get around this problem, could be to 
fashion a cytology shaped device made of foam. At the same time foam was significantly  better 
than the glove and once again this could only be down to its larger surface area compared to the 
glove. We have therefore decided that  despite the fact that  as described in this chapter the glove was 
the least efficient way to collect mucus DNA, we would use a rectal tube catheter (made of latex 
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and hence more similar to glove) for our clinical experiments (chapter 7). There were several 
reasons for this decision. It is a device regularly used by colorectal surgeons to drain/wash the 
rectum, it is acceptable by patients (easier to recruit patients) and therefore more likely to be 
approved by an ethics committee, and finally it would have been very time consuming and costly to 
design, test and get approval for a novel device made of foam in the shape of a brush to use in 
patients.
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6. Is there a gradient of DNA concentration in colonic mucus from the tumour site 
 proximally or distally?
 
 6.1 Objectives
i. To establish the amount of DNA at tumour sites and set  distances proximally and 
distally from the tumour site and to identify if there is a pattern or not.
 
 6.2 Methodology 
Principles of methods
• Fresh colonic specimens resected from cancer patients were cut open by a consultant 
pathologist
• Mucus was sampled using collecting devices as described below at the tumour site, and at 
distances distally  (5-10 and 10-15cm) and proximally  (5-10, 10-20 and 20-40cm) depending 
on length of the surgical specimen
• Mucus samples were taken at the proximal resection margin and along with all 
measurements >20 cm proximal to tumour site were, used to establish the background level 
of colonic DNA exfoliation 
• Values at each location were expressed as the ratio to the value at the tumour site to allow 
comparison between measurements taken from different colons and to allow for differences 
in bowel preparation patients had received between right and left side bowel resections and 
differences in exfoliation rates by different individuals and tumours.
Collection of surgical specimens and sampling of colonic mucus
The colonic surgical specimen was collected and cut open as described in chapter 4.2.1. 
Once the colon was opened, areas of uncontaminated (stool free) mucosa were identified for 
sampling and their distance from the tumour site recorded. A piece of foam or glove with a surface 
area of 4cm2 was applied to the sampling area for a total of ten seconds. To ensure that the same 
force/pressure was applied during sampling, a fixed weight (20g) was applied on top of the piece of 
glove. Care was taken to avoid any  scraping movements that would result in sampling mucosa 
instead of mucus. A further sample was taken using a cytology brush as a positive control.
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Following sampling mucus, the pieces of glove or foam were placed in 15ml Falcon tubes 
(BD Biosciences, USA) containing 3ml of Cell Lysis Solution (Cat No 158908, Qiagen Gmbh, 
Germany). Care was taken to ensure that the entire surface of the glove/foam was covered with cell 
lysis buffer (see Chapter 4). The samples were then stored at room temperature and transferred to 
the laboratory.
Extraction of DNA from colonic mucus samples
Principles of method
• As described in chapter 4.2.1.
DNA extraction was performed following the protocol described in section 4.2.1.
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6.3  Results
The same twenty five colonic specimens were sampled as described in section 5.2. Samples were 
taken using both glove (n=117) and foam  (n=118). The DNA amount in each sample was measured 
and expressed as a ratio to the DNA amount over the tumour site (DNA at distance X/ DNA at 
tumour site). Twenty five (25) mucus samples were taken directly over tumour sites and at specific 
distance ranges as summarised in table 6.1 using both modalities. 
GLOVE N=117 Mean SD 95% CI Median IQR
10-15cm 
Distal to Tumour 21 0.284 0.142 0.220 0.349 0.251 0.129
5-10cm 
Distal to Tumour 19 0.402 0.217 0.297 0.506 0.410 0.380
Tumour site 25 1 - - - 1 -
5-10cm 
Proximal to Tumour 10 0.354 0.216 0.200 0.509 0.333 0.261
10-20cm 
Proximal to Tumour 18 0.231 0.145 0.156 0.305 0.218 0.224
20-40cm
Proximal to Tumour 24 0.140 0.077 0.107 0.172 0.118 0.126
FOAM N=118 Mean SD 95% CI Median IQR
10-15cm 
Distal to Tumour 22 0.323 0.153 0.255 0.391 0.307 0.213
5-10cm 
Distal to Tumour 19 0.459 0.169 0.378 0.541 0.510 0.262
Tumour site 25 1 - - - 1 -
5-10cm 
Proximal to Tumour 10 0.372 0.205 0.225 0.518 0.324 0.233
10-20cm 
Proximal to Tumour 18 0.246 0.126 0.182 0.311 0.231 0.158
20-40cm
Proximal to Tumour 24 0.132 0.081 0.098 0.166 0.123 0.089
Table 6.1: Ratio of DNA amount in colonic mucus at specific distances to tumour site using    
     Glove and Foam to sample mucus from colonic surgical specimens.
The data collected from both using foam and glove were analysed using SPSS v19 (IBM Inc, USA) 
to test for normality (Kolmogorov-Smirnov test). In the glove group data were found to be non 
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normally distributed in the proximal 20-40cm (D(24)=0.192, p=0.023) but were normally 
distributed in the remaining groups (10-15cm distal to tumour (D(21)=0.183, p=0.066, 5-10 distal 
(D(19)=0.102, p=0.200), 5-10 proximal (D(10)=0.215, p=0.200), 10-20cm proximal (D(17)=0.143, 
p=0.200)). Lavene’s test (F(4,86)=4.030, p=0.005) showed that the homogeneity of variance was 
violated in these data and therefore, nonparametric tests were used to analyse and report the results 
of this experiment.  Similarly  the data in the foam group  were also parametric (10-15 distal D(22)
=0.167, p=0.111, 5-10 distal (D(19)=0.145, p=0.200), 5-10 proximal (D(10)=0.226, p=0.161), 
10-20cm proximal (D(17)=0.167, p=0.200), 20-40cm (D(24)=0.139, p=0.200)) but  Lavene’s test (F
(4,87)=3.768, p=0.007) showed that the homogeneity  of variance was violated in these data hence 
non-parametric tests were used again. 
Figure 6.1 summarises the ratio of DNA measured at the set distances to DNA at tumour site. 
Figure 6.1: Median of Ratio of DNA measured at each distance / DNA at the tumour site. D=distal   
      to tumour, P=proximal to tumour.
A Kruskal-Wallis test was used to compare the median ratios at these distances which were found to 
be significantly different both when using glove (H(4)=28.307 p=0.0001) and foam (H(4)=40.440 
p=0.0001) to collect the mucus. Three Mann-Whitney  tests were used as post hoc tests with a 
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Bonferronni correction to compare median values between specific distances. Of note, as three post 
hoc tests were performed the results were reported to a 0.0167 level of significance182. When mucus 
was collected with glove, the median ratio at a distance of 10-15cm distal to tumour site 
(Mdn=0.251 IQR=0.129) was significantly higher than that at a distance more than 20cm proximal 
to the tumour site (Mdn=0.118 IQR=0.126) Mann-Whitney U= 77.0, z=-3.982 p=0.0001 (<0.0167). 
The median ratio at a distance of 10-15cm distal to tumour site (Mdn=0.251 IQR=0.129) was not 
significantly higher than that at a distance 10-20cm proximal to the tumour site (Mdn=0.218 
IQR=0.224) Mann-Whitney U= 135.00, z=-1.277 p=0.209 (>0.0167). At the same time, the median 
ratio at a distance 5 to 10cm distal to tumour site (Mdn=0.410 IQR=0.380) was not significantly 
higher than the same distance proximal to the tumour site (Mdn=0.333 IQR=0.261) Mann-Whitney 
U= 80.5, z=-0.666 p=0.512 (>0.0167). 
When mucus was collected with foam a similar pattern of DNA ratio was observed. The median 
ratio at a distance of 10-15cm distal to tumour site (Mdn=0.307 IQR=0.213) was significantly 
higher than that  at  a distance more than 20cm proximal to the tumour site (Mdn=0.123 IQR=0.089) 
Mann-Whitney U= 61.5, z=-4.455 p=0.0001 (<0.0167) while it  was not significantly higher than 
that at a distance 10 to 20cm proximal to the tumour site (Mdn=0.231 IQR=0.158) Mann-Whitney 
U= 142.0, z=-1.275 p=0.210 (>0.0167). The median ratio at a distance 5 to 10cm distal to tumour 
site (Mdn=0.510 IQR=0.262) was not significantly  higher than the same distance proximal to the 
tumour site (Mdn=0.324 IQR=0.233) Mann-Whitney U= 65.0, z=-1.377 p=0.179 (>0.0167)
Table 6.2 summarises the results of this analysis.
Distal 10-15cm 
v.
Proximal 10-20cm
Distal 5-10cm 
v. 
Proximal  5-10cm
Distal 10-15cm 
v.
Proximal 20-40cm
Glove Not Significant Not Significant Significant
Foam Not Significant Not Significant Significant
Table 6.2: Comparing median DNA ratio between three distances. Summary of statistical analysis.
    Significant=p<0.0167, Non significant p>0.0167.
As described in section 6.2, measurements taken more than 20cm proximally from the tumour site 
can be assumed to represent the background DNA value of each colon.
It is interesting to repeat the analysis by grouping all measurements taken by  glove distally  to the 
tumour and compare them with those taken proximally and those taken from the background colon.
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Twenty seven (27) measurements were taken from proximal sites, 40 from distal, 24 from 
background sites using glove and 27, 41 and 24 respectively using foam. Table 6.3 summarises the 
results of these measurements. 
Background Proximal Distal
Modality Mean Median SD IQR Mean Median SD IQR Mean Median SD IQR
Glove 0.140 0.118 0.07 0.13 0.276 0.25 0.18 0.24 0.340 0.29 0.19 0.27
Foam 0.132 0.123 0.08 0.09 0.293 0.240 0.17 0.18 0.386 0.393 0.17 0.35
Table 6.3: Ratio of DNA amount in colonic mucus at proximal, distal and background sites using 
     glove and foam to sample mucus from colonic surgical specimens. 
The data collected both using foam and glove were analysed using SPSS v19 (IBM Inc, USA) to 
test for normality (Kolmogorov-Smirnov test). Foam data (Proximal, D(27)=0.142, p=0.173, Distal 
D(41)=0.126, p=0.102, Background D(24)=0.139, p=0.200) were parametric but once again 
Lavene’s test (F(2,89)=7.277, p=0.001) showed that the homogeneity  of variance was violated in 
these data. The Glove data were similar and again non-parametric tests were used to analyse and 
report the results in both foam and glove data.
Figure 6.3 summarises the ratio of DNA at distal, proximal and background sites to tumour site 
using glove and foam.
A Kruskal-Wallis test was used to compare the median ratio at distal, proximal and background sites 
which were found to be significantly different both when using glove (H(2)=23.888 p=0.0001) and 
foam (H(2)=34.384 p=0.0001) to collect the mucus. Three Mann-Whitney tests were used as post-
hoc tests with a Bonferronni correction to compare median values between specific distances. Of 
note, as three post hoc tests were performed the results were reported to a 0.0167 level of 
significance181.
When using a glove the distal median ratio (Mdn=0.290 IQR=0.265) was significantly higher than 
that at the background site (Mdn=0.118 IQR=0.126) Mann-Whitney U= 132.0, z=-4.827 p=0.0001 
(<0.0167). The proximal median ratio (Mdn=0.250 IQR=0.246) was also significant when 
compared against the background site Mann-Whitney  U= 152.0, z=-3.246 p=0.001 (<0.0167). 
Interestingly  the Proximal median ratio (Mdn=0.250 IQR=0.246) was not significantly  lower than 
the distal ratio (Mdn=0.290 IQR=0.265) Mann-Whitney U= 429.5, z=-1.413 p=0.158 (>0.0167). 
In the foam group the results were similar, and again both proximal (Mdn=0.240 IQR=0.184) and 
distal median ratio (Mdn=0.393 IQR=0.350) were significantly different when compared to the 
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background median ratio (Mdn=0.123 IQR=0.089), Mann-Whitney U= 108.0, z=-4.077 p=0.0001 
(<0.0167) and Mann-Whitney U= 82.5, z=-5.568 p=0.0001 (<0.0167) respectively.
Figure 6.2: Median ratio of DNA at distal, proximal and background sites to tumour site using    
      glove and foam.
As in the glove group, the foam median proximal and distal ratio were not significantly different 
Mann-Whitney U= 386, z=-2.100 p=0.036 (>0.0167). Table 6.4 summarises the statistical analysis.  
Distal v. Background Proximal v. Background Distal v. Proximal
Glove Significant Significant Non Significant
Foam Significant Significant Non Significant
Table 6.4: Comparing median DNA ratio between three grouped sites. Summary of statistical   
      analysis. Significant=p<0.0167, Non significant=p>0.0167.
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  6.4  Discussion
The mucus layer over the tumour site in this study  demonstrated significantly higher counts of 
DNA compared to both adjacent and distant sites along the colon. This is in agreement with 
published data160. The amounts of DNA found in non tumour site was several orders of magnitude 
lower compared to the tumour site even at distances within 5cm from the tumour site. Interestingly 
there is no significant difference in the amount of DNA found in the mucus between distal and 
proximal sites in relation to tumour within the colon when the measurements are taken within 
15-20cm. This implies a ‘volcano’ effect of cell exfoliation from tumour sites, with the tumour 
being the ‘crater’ and DNA being the ‘lava’ being ‘expelled’ (exfoliated) and distributed evenly 
around the tumour site. However, in this study when distal sites to tumour (up  to 15cm) were 
compared to sites more than 20cm proximal to the tumour there was a significant increase in DNA 
counts. This points to the conclusion that at these distances the above ‘volcano’ effect stops and the 
DNA found represents colonocyte DNA exfoliation as part of the physiological regeneration of 
human colonic mucosa. When we grouped together the measurements from all distal sites and 
compared them to background DNA counts, they  were significantly  higher as were the grouped 
proximal sites. When we compared the grouped proximal to the grouped distal sites, again there 
seem to be no difference, indicating that there is a ‘volcano’ effect  of DNA exfoliation around the 
tumour.
Unfortunately the maximum distances from the tumour sites were limited to the macroscopic 
clearance of our 25 surgical specimens, with 15cm and 40cm being the maximum distal and 
proximal resection margins respectively. These maximum distances were related to whether the 
specimen was from a right colectomy (specimens with longer distal distances but lower proximal 
distance) or a left colectomy (specimens with longer proximal and shorter distal distances). Ideally 
we would prefer to have taken measurements along the entire length of the colon in each specimen 
but that would only have been possible if the patients underwent a total colectomy. This operation is 
usually  indicated for synchronous tumours or in patients with polyposis syndromes, both of which 
would have different exfoliation characteristics to a single site tumour. 
It will be interesting to see if there is indeed an increased accumulation of DNA at the rectum of 
cancer patients. Two recent studies180, 181 have showed this effect, namely accumulation of higher 
than normal DNA in the rectal mucus of patients with colonic cancers. In chapter 7 we measure and 
analyse DNA from samples taken from rectal mucus of patients with cancer.
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7.         Can we use DNA isolated from rectal mucus to detect colorectal cancer?
 7.1  Objectives
  i. To identify if there is a significant  difference in the amount of DNA extracted from 
  sampled rectal mucus between patients with neoplasia and those without.
  
  ii. To identify  when a patient has CRC by  using a three markers methylation panel 
  assay on DNA isolated from rectal mucus in symptomatic patients referred to 
  a colorectal clinic.
 7.2 Methodology
  
  7.2.1 Comparing DNA content in rectal mucus samples from symptomatic 
           colorectal patients.
Patient recruitment, consent procedure and sampling rectal mucus
The following studies have been approved by the National Research Ethics Committee South 
Central Oxford C (ref 11/SC/0305) and the Oxford University Hospitals NHS Trust Research and 
Development department (ref PID 6425). 
Participants were identified following referral by their General Practitioner to specialist outpatient 
clinics (colorectal and gastroenterology) or the ward for investigation of bowel symptoms 
suspicious of bowel cancer. The patients were sent details of the study (for patient information sheet 
and invitation letter see Appendix I) prior to attending the clinic by the study team. At the clinic 
patients were given the opportunity  to discuss any aspects of the study  and sign the consent form. 
A digital rectal examination was performed to identify  any palpable tumour/polyps and if present, 
the patient was excluded. Proctoscopy using a standard proctoscope was performed and a rectal 
catheter (30Fr, PTFE Coated Latex, C.R Bard Inc, USA) was inserted into the rectum. The balloon 
was then inflated using air to 40ml so as to touch the lower rectal wall, then deflated and retracted 
avoiding touching the inside wall of the proctoscope to reduce trauma to the mucosa. The lower 
10cm of the rectal catheter was then immersed in a 15ml Falcon tube (BD Biosciences, USA) 
containing 3ml of Cell Lysis Solution (Cat No 158908, Qiagen Gmbh, Germany). Following sample 
collection patients underwent the standard investigations for their symptoms, namely colonoscopy 
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or CT colonoscopy. Their final diagnosis (neoplasia, benign disease or normal investigation) was 
recorded. DNA extracted from the rectal catheter was measured using the following protocol. 
Extraction and measurement of DNA from patient rectal mucus samples
Principles of method
• The four main principles of the protocol are those described in 4.2.1.
Protocol (Modified Gentra Puregene Kit body fluid protocol, Qiagen Gmbh, Germany) 
• Samples were incubated for 1 hour at 66 oC. 
• To maximise yield 90µL of Puregene Proteinase K (Cat no 158918, Qiagen Gmbh, Germany) was 
added.
• To ensure RNA free DNA 90µL of RNase A solution (Cat No 158924, Qiagen Gmbh, Germany) 
was added and Falcon tubes incubated for 15min at 37 oC. Samples were then cooled down by 
placing on ice for five minutes. 
• 6mL of protein precipitation solution (Cat No 158912, Qiagen Gmbh, Germany), to separate 
proteins from DNA, was added and Vortex at high speed for 20 seconds. Samples were then 
incubated in ice for 5 minutes and then centrifuged for 10min at 2,000g.
• The resultant supernatant containing DNA added to a clean 50ml Falcon tube containing 18ml of 
isopropanol and 30µL of Glycogen (Cat No 158930, Qiagen Gmbh, Germany). The samples were 
mixed gently by inverting 50 times and incubated at room temperature for 5 minutes. 
• They  were centrifuged for 10min at 2,000g to form a DNA pellet. The supernatant  was carefully 
discarded, taking care the DNA pellet was not dislodged. Visual verification of the DNA pellet 
was done. 
• 18ml of 70% ethanol was added to wash the DNA pellet and samples were centrifuged for 1min at 
2,000g.
• The supernatant was drained again taking care the DNA pellet was not dislodged and samples 
were allowed to air dry for 15minutes.
• 300µL of DNA Hydration solution (Cat No 158914, Qiagen Gmbh, Germany) was added and the 
sample vortexed for 5 seconds at medium speed and incubated at 65 oC for 1hour to hydrate the 
DNA.
• The samples were then stored overnight with gentle shaking using a 3D Rocking Platform STR9 
(Stuart Scientific, UK).
• Samples were centrifuged briefly (Capsulefuge PMC-100 Tomy Teoh, USA) for a few seconds 
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the next morning, before measuring their DNA content using a spectrophotometer.
The ND1000 Spectrophotometer (Nanodrop® Tech Inc, USA) was used to measure the DNA 
concentration in each sample as described in section 4.2.1. Using the concentration value of DNA 
per sample we calculated its content and expressed the results as total DNA isolated in ng from each 
patient.
    7.2.2 Using a three biomarker panel assay to diagnose CRC from DNA isolated 
                 form rectal mucus in symptomatic colorectal patients.
The methylation markers
Numerous biomarkers have been described123-126. For the purposes of this project three methylation 
markers were chosen due to a combination of scientific evidence and availability from collaborating 
teams. The following three methylation markers have been reviewed recently183-185 and appear to be 
promising candidates for CRC detection in stool DNA and have showed promising results in early 
studies with high sensitivity and specificities in both CRC tissue and stool based studies 
(summarised below for each marker).
N-Myc Downstream Regulated Gene 4 (NDRG4)
NDRG4 is a potential tumour suppression gene which has been identified in a variety of tumours 
and cancer cell lines. In 2009 Melotte et  al183 also demonstrated that the NDRG4 promoter was 
methylated in CRC. It was present in 86% and 70% of two independent series of mucosa samples 
from CRC tissue, while present in only 4% of non CRC mucosa. Stool samples from 75 CRC 
patients and healthy  matched controls were tested for methylation of NDRG4 using quantitative 
methylation-specific PCR with a sensitivity  of 53% and specificity of 100%. In addition, although 
CpG methylation is more commonly associated with more proximal tumours, NDRG4 was found to 
be methylated to similar levels in proximal (mostly MSI) tumours and distal (mostly CIN) tumours. 
This may make a useful biomarker for both MSI and CIN CRC.
Tissue Factor Pathway Inhibitor 2 (TFPI2)
TFPI2 is a Kunitz-type serine proteinase inhibitor that protects the extracellular matrix of cancer 
cells from degradation and inhibits in vitro colony formation and proliferation184,185. It is thought 
that loss of TFPI2 function could predispose cells toward a pro invasive program, consistent  with an 
important role for this protein in later stages of carcinogenesis. Glockner et al186  in 2009 
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demonstrated methylation of TFPI2 in 99% of CRC tissue. Stool samples from CRC and healthy 
controls were tested for methylated TFPI2 showing sensitivity of 75%-89% and specificity of 
79-93%.
GATA Binding Protein 4 (GATA4)
GATA4 is involved in development of the gastrointestinal tract. Hellebrekers et al187 in 2009 
demonstrated that GATA4 had tumour suppressor properties in CRC and was methylated in 70% of 
CRC tissues but  only in 6% of normal control mucosa from healthy  non cancer individuals. When 
testing stool DNA from 75 known CRCs and 75 healthy individuals for methylation of GATA4 they 
demonstrated sensitivity of 71% and specificity of 84%.  
DNA was extracted as described above (section 7.2.1) from rectal mucus collected from 
symptomatic colorectal patients. Samples were blinded and then handed over to an experienced 
laboratory technician (Dr Kim A.D. Wouters) working with Dr Manon Van Engeland in GROW–
School for Oncology and Developmental Biology, Maastricht University  Medical Centre, The 
Netherlands.
The protocol for the methylation assay is described in detail in Hellebrekers et al187 and Melotte et 
al183. The major steps in this assay are sodium bisulfite conversion, sequencing, and quantitative 
methylation-specific PCR. A positive assay was defined as more than two markers methylated. The 
final diagnosis for each patient was recorded as described above (section 7.2.1).
 7.3  Results
  7.3.1  Comparing DNA counts in rectal  mucus samples from symptomatic 
               colorectal patients.
Fifty eight  (58) patients consented to rectal sampling using the method described above. Twenty 
four (24) were women. All patients were sampled prior to receiving any laxatives or bowel 
preparation. Fifty  seven patients received colonoscopy as their method of investigating their 
colorectal symptoms. One patient had a flexible sigmoidoscopy and a CTC in view of co-
morbidities and age, which were both reported as normal. Patients presented with bleeding per 
rectum (22), iron deficiency anaemia (11) and change in bowel habit  (25). Thirty nine (39) were 
eventually diagnosed with colorectal cancer (32 had tumours in the left colon), 4 patients had 
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benign polyps (with low grade dysplasia adenomas <1cm) and 15 had no colonic disease at  all. 
Twenty patients were within the target age group  (60-69) for CRC screening in England, 5 of which 
were diagnosed with cancer. None of the twenty eligible patients had participated in a screening 
cycle prior to clinic attendance. Only  one patient diagnosed with cancer had a mucinous 
adenocarcinoma on final histology while the remainder had conventional adenocarcinomas. Table 
7.1 summarises the two groups (benign and CRC) of patients while figure 7.1 shows the median 
DNA isolated from each group of patients.
Benign Cancer
Sex Men=12   Women=7   Men=22           Women=17
Screening Age (60-69) 5 14
Site of lesion N/A   Left=32              Right=7
Dukes Staging N/A    A=3       B=15     C=21
Table 7.1: Summary of demographics, lesion site and staging in patients with and without   
      colorectal cancer.
The data sets from both groups were tested using SPSS v19 (IBM  Inc, USA) to test for normality 
(Kolmogorov-Smirnov test) and homogeneity  of variance (Lavene’s test). Benign data were non 
parametric (benign, D(19)=0.173,p=.0137) while cancer data were parametric (cancer, D(39)
=0.192, p=0.001) but the homogeneity of variance was violated in these dataset (F(2,56)=18.270, 
p=0.0001) and therefore non parametric statistical analysis was performed. 
The patients diagnosed with cancer had significantly higher amounts of DNA in their rectal mucus 
1247000.0 ng compared to those with benign disease 33575.0 ng, Mann-Whitney  U= 212, z=-2.626 
p=0.009. The CRC patients were further analysed using Mann-Whitney tests to look for any 
differences in the DNA amounts isolated between patients with right v left colonic lesions, men v 
women, patients with different Dukes staging or patients within the screening target age or not. 
Because of small numbers, patients with Dukes A and B were grouped together and compared to 
those with Dukes C. Table 7.2 summarises the above analysis.
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Figure 7.1: Medians of DNA amount collected from rectal mucus from symptomatic patients with a 
       diagnosis of cancer and not.
Finally, median DNA isolated from left  colonic lesions (Median=119,575ng) was significantly 
higher compared to the median DNA amount from benign patients, Mann-Whitney U= 164, 
z=-2.934 p=0.003. Interestingly this was not the case for tumours on the right side of the colon 
Mann-Whitney U= 48, z=-1.217 p=0.240.
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P=0.009
Cancer
Sex Men
N=22
Women
N=17
Median=126,871 (IQR=307,960) Median=108,121 (IQR=271,577.5) P=0.590
Age Screening Age (60-69)
N=14
Non-Screening Age
N=25
Median=227,189.1(IQR=292,387.8) Median=108,733.83 (IQR=272,677.5) P=0.251
Site Left Colon
N=32
Right Colon
N=7
Median=119,575.0 (IQR=233,720) Median=339,600.0 (IQR=582032) P=0.608
Staging Dukes A+B
N=18
Dukes C
N=21
Median=126,871 (IQR 218,533) Median=108,121 (IQR 324,625) P=0.922
Table 7.2: Median DNA in ng isolated from rectal mucus from symptomatic colorectal patients 
      diagnosed with cancer.
   
 
  7.3.1  Using a three biomarker panel assay to diagnose CRC from DNA isolated    
            from rectal mucus in symptomatic colorectal patients.
The panel of biomarkers was positive in 48 patients (83%). In the majority  (35/48) of these positive 
tests all three markers were methylated (73%). Thirty five patients were correctly identified as 
having cancer by the biomarker panel assay  while 5 cases of cancer had a negative test. Out of the 
missed cancer cases three had only  one methylated marker positive (TFPI2) while the remaining 
two showed no methylation at all. In addition there were thirteen patients that had positive tests but 
had no cancer, the majority (11) having all three markers methylated. Overall, there were 35 true 
positives, 5 true negatives, 13 false positives and 5 false negatives. The sensitivity of the three 
marker test was 87.5% with a specificity  of 27.5%. SPSS v19 (IBM  Inc, USA) was used to 
calculate the Kappa measure of agreement188 along with likelihood ratios and positive and negative 
predictive values. A slight measure of agreement (K=0.174,  p=0.154) was shown between the three 
marker panel and standard diagnostic tests for CRC . The positive likelihood ratio +LR was 1.21 
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while negative likelihood ration -LR was 0.45 with a positive predictive value of 72.9% and 
negative prediction value of 50%.
Marker Sensitivity Specificity PPV NPV
NDRG4182 72.5% 27.8% 69% 80%
TFPI2183 92.5% 11.1% 69.8% 40%
GATA4184 72.5% 33.3% 72.9% 33%
All three 87.5% 27.5% 72.9% 50%
Table 7.3: Summary of sensitivity, specificity, positive predictive value (PPV) and negative   
      predictive value (NPV) of DNA methylation assay on DNA isolated from rectal mucus. 
The performance of each marker alone was also analysed. NDRG4 identified correctly 29 patients 
with cancer (true positives), 5 without cancer (true negative), 13 patients had methylated NDGR4 
but had no cancer (false positives) and 11 patients had un-methylated NDGR4 but actually had 
cancer (false negatives). The overall sensitivity  was 72.5%, specificity of 27.8% with a slight 
measure of agreement (K=0.003, p=0.983). PPV was 69%, NNV= 80% and a +LR=1 and 
LR=0.09. Twenty nine patients were correctly diagnosed with cancer by GATA4 and 6 were 
identified as normal. Eleven cases were identified as having cancer but actually had no CRC, while 
12 patients were identified as normal but actually had CRC. The sensitivity was 72.5%, specificity 
of 33.3% with moderate measure of agreement (K=0.59 p=0.652). PPV was 72.9%, NNV= 33% 
and a +LR=1.1 while -LR=0.83. Finally when using TFPI2 alone we identified correctly 37 
cancers, missed 3, while 2 patients were correctly  cleared of CRC and 16 had cancer while the 
marker was un-methylated. Sensitivity  for TFPI2 was 92.5, specificity 11.1%, with a slight measure 
of agreement (K=0.045, p=0.650). PPV was 69.8%, NNV= 40% and positive LR of 1.1 and 
negative LR of 0.68. Table 7.3 summarises and compares sensitivity, specificity PPV and NVP 
between the three markers and the panel.
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 7.4  Discussion
The idea of measuring DNA from exfoliated colonocytes in stool as a screening methods has been 
previously  described187-189. Two recent studies180, 181 have also used rectal mucus instead of stool. 
We showed higher DNA amounts in patients with CRC in agreement with the above two studies. 
Mahadavan et al191 in 2012 published a large cohort study where 828 patients with symptom of 
colorectal disease had rectal mucus samples taken and their DNA concentration measured. 10% of 
those patients were diagnosed with CRC (colonoscopy, CTC or barium enema). The DNA 
concentration was significantly  higher in patients with CRC. In addition, studies have reported 
secondary  distal tumours177-179 in colorectal cancer patients, via re-implantation of viable tumour 
cells at sites distal to the tumour. Our findings, the accumulation of DNA in rectal mucosa in cancer 
patients along with the higher DNA counts found at distal sites up to15cm from the tumour site 
compared to background sites (chapter 6) and the well described secondary distal metachronus 
tumours, suggest that there is DNA transported along the MCL in such patients. As previously 
described180, 181 staging of CRC does not affect the amount of DNA isolated from the rectal mucus 
of such patients. Our findings supports that observation as we found no difference in the amount of 
DNA isolated from patients with Dukes stage A or B compared to C.
In our study  there was no significant difference in the amount of DNA isolated from patients with 
left compared to right lesions which contradicts both of these studies180, 181 which demonstrated 
higher counts of DNA in rectal mucus samples from patients with lesions distal to the splenic 
flexure. However, we too have demonstrated that patients with tumours in the left colon have higher 
DNA amounts in their rectal mucus compared to controls. Right sided tumours gave rise to an 
increased amount rectal mucus DNA compared to controls which did not reach statistical 
significance, in agreement  with Loktionov et al180. One explanation for the difference in DNA 
detected between right tumours v controls and left tumours v controls is that this could reflect the 
differences in the biological and oncological characteristics of right and left tumours (MSI v CIN) 
as previously described192. It is possible to suggest  that most of the colonocytes exfoliated by right 
sided tumours have died by the time they reach the rectum as they  have a much longer distance to 
travel on the MCL. As described in section 1.3, exfoliating cancer colonocytes have certain survival 
advantages (eg loss of anoikis) compared to normal colonocytes that allow them to survive for 
longer in the colonic lumen. This ‘extra survival time’ could potentially  expire by the time such 
cells reach the rectum if have originated from the right colon, given the longer distance they need to 
travel. Normal colonic transit times may  however be impaired in patients with CRC due to 
obstructive symptoms or excessive secretion of mucus causing diarrhoea. Further detailed work 
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would need to be done in order to determine the inter-relation of these factors.
In both of the previously  published studies, the authors proposed using quantitative DNA assays as 
a screening method for colorectal cancer. However to do that, a cut off value of DNA detected 
needs to be defined above which such a test will be positive. However we have found in our study 
there was large variation in the amount of DNA detected in both patients with CRC (range 
2455-923,000ng) and those without (range 170-152,000ng). In the two previously  studies a cut off 
value was calculated using statistical methodology. Interestingly  Mahadavan et al191 in 2012 used 
the cut off DNA values suggested by earlier studies180, 181 along with other parameters suggestive of 
CRC such as lower GI bleeding, positive FOBT, age, CEA and male sex in a large cohort  study  to 
try to diagnose CRC. They concluded that DNA amount on its own was unreliable to diagnose 
CRC. In 2013 Bajwa et al193 used rectal mucus DNA quantitate analysis in 467 patients referred 
with colorectal symptoms. One of the aims of the study was to define a cut off value of total DNA 
concentration that  will attain a specificity  of at least 60%. They proposed a value of >1.4mg/l a 
value different from all three previously published values, highlighting the challenges of DNA 
quantitative analysis alone as a screening tool for CRC. It is clear from the above that even by  using 
a large number of patients quantitative DNA analysis form rectal mucus is not sufficient to reliably 
diagnose colorectal neoplasia. 
We used the DNA isolated from the rectal mucus of symptomatic patients to test for presence of 
methylated biomarkers as described above. Our three methylation marker panel test was good in 
identifying CRC with a sensitivity of 87.5%. Unfortunately  we observed a very high rate of false 
positives in our control group of symptomatic patients, resulting in an unacceptably  low specificity 
of 27.5%. When the performance of each of the markers was analysed individually, we observed 
again good sensitivity  but unfortunately low specificities, reflecting the high false positive rates. 
The low sensitivity contradicts the published performance183,186,187 of these markers in DNA 
isolated from stool from cancer patients and healthy  volunteers. Reasons for the higher then 
expected false positives observed in our study could be due to differences in our patient’s 
demographics and those of the published study  populations, or related to the assay  used or  due to 
logistical problems. 
Our patients were undiagnosed and symptomatic and therefore were referred to a colorectal clinic 
for urgent investigation. The populations of the three previously published studies were already 
known to have CRC or not and the control groups were healthy volunteers. In the NDGR4183 and 
TFPI2186 studies the authors noted a significant difference in age between the CRC and control 
groups (younger controls compared to CRC patients). In our study  the two groups were matched for 
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age (no significant difference, p<0.005). Background aberrant methylation in normal colonic 
mucosa increases with age29 and therefore we would expect a slightly higher prevalence of 
methylation markers in healthy colonic mucosa as age increases. However this age related increase 
is unlikely  to be enough to explain the very high positive false positive results we have observed in 
our study. It is unlikely that the above differences (age and symptomatic v asymptomatic) in the two 
populations fully  explains the low specificity  we have observed. The above previously 
published183,186,187 studies validated their methylation assay using a statistical model to identify  a cut 
off value to consider the marker as positively methylated to achieve acceptable sensitivity and 
specificity. To do so they used training sets of DNA isolated from the stool samples of CRC patients 
and healthy individuals. It is possible that the methylation cut off value might be different for DNA 
isolated from mucus. In other words it  is plausible that the value at which methylation is positive 
might be higher for DNA isolated from mucus compared to stool due to more pure/clean DNA 
isolated. To isolate DNA from stool, a full motion of stool is used which is then processed to isolate 
human DNA (about 1% of total DNA isolated) and to neutralise PCR inhibitors. In contrast, in our 
method of collection, only a very tiny amount of rectal mucus is required and a very simple process 
(Chapter 4) is used to isolate large amounts of human DNA. If we assume that a higher threshold 
for methylation positivity  is required then that could explain our low specificity  as well as our 
slightly higher sensitivity  rates. A validation study where a threshold is calculated for DNA isolated 
from mucus will confirm or reject this explanation. Finally  technical or logistical mistakes are very 
unlikely as the methylation assays were performed in the laboratory that published two183,186 out of 
the three studies on these markers, by a very experienced scientist who was co-author in both 
previous publications. A mislabelling mistake is also unlikely  as the samples were labelled at the 
time of collection and DNA in each sample was isolated and its concentration measured in the UK 
and then sent to the The Netherlands. The quantitive DNA results (section 7.3.1) suggest that there 
was no mislabeling between CRC and controls and in addition the results from The Netherlands 
were reported using the original UK samples identification system. 
In conclusion our three methylation marker panel has not performed as expected and was not able 
to reliable identify and exclude CRC in our study  population. Further work (see chapter 8) will 
identify if this is due to the sampling technique or the markers used.
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8. Conclusion and future work
Most current early detection and screening strategies for CRC use stool samples to look for blood 
DNA or other biomarkers. It is a fairly novel concept to use rectal mucus as the material of choice. 
This project has explored the feasibility of obtaining reliable rectal mucus samples in order to 
obtain DNA and look for biomarkers. There are several major problems which will need to be 
overcome in order to translate this concept into a clinical tool. Firstly, rectal mucus may be 
contaminated with stool, blood and or rectal mucosa tissue and therefore obtaining rectal mucus 
may be no better than directly sampling the mucosa, stool or blood. Secondly, rectal mucus may 
contain DNA from various sources including exfoliated colonocytes, blood, bacteria, ingested 
materials or contamination from collecting devices. 
Exfoliated colonocytes or tissue and blood dislodged from the surface of a tumour may  all be useful 
in contributing to the DNA extracted from rectal mucus for diagnostic purposes. Blood or mucosa 
from the normal rectal epithelium dislodged by trauma from the collecting device may  confound the 
results of such tests. DNA from non human sources does not have the same light absorption 
properties as human DNA and therefore specimens contaminated with significant amounts of these 
types of DNA would be excluded from further analysis when the purity of DNA samples was tested.
Collection and storage of rectal mucus
In order to test our hypothesis we first needed to prove that it  was possible to collect, safely store 
and accurately  measure the DNA content of colonic mucus. The result of our first set of 
experiments (chapter 4) showed that  it is possible to reliably use a piece of latex glove to sample 
colonic mucus and extract its DNA content. The results were reproducible when we repeated the 
experiment. In addition we took repeated measurements at  a specific location within the colonic 
specimens and got  consistent DNA counts indicating that the total amount of DNA in the colonic 
mucosa is uniformly distributed around the circumference of the colon. 
The total DNA extracted from rectal mucus may include DNA from several sources (see above) as 
well as the colonocytes exfoliated from the surface mucosa. It  would be useful to perform 
cytological examination of mucus smears in parallel with DNA assay from the same mucus sample 
in order to check that at least some of the DNA obtained originated in colonocytes.
We also demonstrated that cell lysis buffer should be used to store our collecting device prior to 
DNA extraction. These results allowed us to proceed to the next stage of the project to test  our 
hypothesis.
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Collection Device
The next step  was to identify which material was the best for yielding the highest DNA counts in 
mucus sampled from fresh colonic specimens excised from patients with CRC. The reasons why the 
three materials were chosen have been described earlier in chapter 5, but in summary  a cytology 
brush was used as positive control, a piece of latex glove as it would simulate a device previously 
used in published studies180, 181 to sample rectal mucus and a piece of foam as potential novel 
material. Ideally it would have been useful to use the same devices as described in Loktionov’s 
seminal papers180, 181. However unfortunately this device was not commercially  available during the 
course of this project
As predicted both glove and foam yielded significantly lower amounts of DNA compared to the 
positive control. Interestingly foam significantly out performed the glove device by yielding double 
the DNA amount compared to glove. We proposed that these observations were due to the 
differences in the effective surface of each material (surface area of brush>foam>glove) and not as 
a result of increased friction to the underlying mucosa and hence possible direct sampling of 
colonocytes). Our hypothesis states that it is possible to detect DNA from proximal sites in the 
colon by sampling rectal mucus in patients with colorectal cancer. As a result we repeated the 
analysis of the results by excluding measurements taken directly over tumour sites to try  and 
simulate the future clinical application of such devices. The performance of each material was 
comparable to our initial analysis although all three materials yielded less DNA than expected 
compared to the initial analysis. 
In conclusion the brush although initially used as a positive control, could indeed be the best 
material to collect mucus. Foam was almost twice as good as glove in yielding DNA from colonic 
mucus samples. This advantage could be simply  due to the larger surface area of a brush and piece 
of foam compared to a piece of glove. 
Despite the fact that glove was the least efficient way  to collect mucus DNA, we decided to use a 
rectal tube catheter (made of latex and hence more similar to glove) for our clinical experiments 
(chapter 7). There are several reasons for this decision. It is a device regularly used by colorectal 
surgeons to drain/wash the rectum, it is acceptable to patients (easier to recruit patients) and 
therefore more likely to be approved by the ethics committee, and finally it would be very  time 
consuming and costly to design, test and get approval for a novel device made of foam in the shape 
of a brush to use in patients. At the same time we used foam and glove to try an establish if there is 
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a gradient of DNA concentration in colonic mucus from the tumour site proximally or distally, as an 
internal control. 
DNA gradient in colorectal mucus
This study  has demonstrated that there is a significantly higher count of DNA in the mucus over the 
tumour site compared to both adjacent and distant sites along the colon. Interestingly there is no 
significant difference in the amount of DNA found in the mucus within 15-20cm either proximal or 
distal to the tumour. This observation implies a ‘volcano’ effect of cell exfoliation from tumours as 
described in chapter 6. 
DNA counts were significantly higher at sites distal to the tumour compared to background DNA 
counts taken at >20cm proximal to the tumour. In addition, as detailed in chapter 7, we found that 
DNA counts were higher in rectal mucus of patients with colorectal cancer compared to control 
patients. These findings, along with the previously  described phenomenon of distal seeding of 
metachronus tumours177-179, suggest that DNA is transported along the MCL in CRC patients. As 
discussed in chapter 6 there are some limitations in our experimental model as the maximum 
proximal and distal distances from tumour were dictated by the length of the resected specimen. 
Ideally we would have preferred to have taken samples along the entire length of the colon in each 
patient but that would only have been possible if the patients underwent a total colectomy. This 
operation is only indicated for synchronous tumours, in patients with polyposis syndromes or 
cancers arising in inflammatory bowel disease, all of which would have different exfoliation 
characteristics to a single site tumour. 
This study  is based upon the assumption that colorectal cancers shed cells containing DNA that can 
be extracted from rectal mucus, and that a higher total DNA count obtained from rectal mucus may 
indicate the presence of  a proximal tumour. However, there is no evidence to confirm or refute the 
hypothesis that normal individuals may have a gradient of DNA concentrations in the MCL from 
proximal to distal colon, with the highest level in their rectal mucus due to normal exfoliation of 
intestinal mucosa. Therefore it may be more appropriate to consider the relative amounts of DNA 
from proximal to distal in an individual colon or between CRC patients and controls at a given site 
such as the rectum, rather than absolute amounts of DNA extracted.
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Rectal mucus DNA yield in CRC 
If rectal mucus is ever to be used as a screening or early diagnosis sample, it is necessary to show 
that either the absolute or relative amounts of rectal mucus DNA are significantly different between 
CRC patients and controls. We demonstrated higher rectal mucus DNA in CRC compared to 
controls, which was not affected by  tumour staging or age of the patients. However the site of the 
tumour did influence rectal DNA counts. Left sided tumours had significantly higher rectal mucus 
DNA counts compared to controls. These observations were in agreement with published 
studies180,181. For right sided tumours there was an increased level of rectal mucus DNA compared 
to controls but this did not reach statistical significance. These finding may be due to the relatively 
small number of cases in this study and a larger population would need to be studied in order to 
confirm or refute this. 
The majority  of cancers arise via the adenoma carcinoma sequence and current screening programs 
aim to detect adenomas which can be removed in preference to established cancers. Due to the 
small number of cases in this study, we did not attempt to distinguish between adenoma and other 
non malignant colorectal disorders. We performed a proof of principle study to try to distinguish 
between cancer and non cancer patients. We also analysed Dukes C cancers separately to the earlier 
stages. This project has shown that although there was a significant difference in the amount of 
rectal mucus DNA between CRC and non CRC samples, there was no significant difference 
between the different Dukes stages.
As discussed in chapter 7, there have been previous attempts to identify a cut off value of rectal 
mucus DNA which would distinguish between CRC and controls. This would have been an ideal 
simple screening method. However, there is high variation in the amounts of DNA isolated from 
rectal mucus, an observation we also confirmed. Two recent  studies191, 193 attempted to establish a 
way of combining quantitative DNA assays using rectal mucus sampling along with other clinical 
parameters to produce a predictive score. These concluded that due to the variation in quantitative 
DNA assays, such scores were not a reliable method for CRC screening. 
Since total DNA assays are not a useful screening tool, it  may be possible that biomarkers in the 
rectal mucus DNA could be used to distinguish between CRC and controls.
Methylation markers
A small number of groups worldwide have studied methylation markers in stool based 
tests123,124,183,186,187. However to our knowledge no group has studied these markers in rectal mucus. 
This project has therefore collaborated with the Maastricht group who performed some of the 
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experimental work described in chapter 7. The three methylation marker panel test  was good at 
identifying CRC with a sensitivity of 87.5%. Unfortunately  we observed a very high rate of false 
positives in our control group, resulting in an unacceptably  low specificity of 27.5%. When the 
performance of each of the markers was analysed individually, we again observed good sensitivity 
but low specificities, reflecting the high false positive rates. The low specificity  in our study 
contradicts the published performance183,186,187 of these markers in DNA isolated from stool in 
cancer patients and healthy volunteers. We concluded that our three methylation marker panel has 
not performed as expected and was not able to reliable identify  and exclude CRC in our study 
population. The very high false positive rates we observed amy be due to the fact  that our control 
population was symptomatic colorectal clinic patients rather healthy volunteers. Non malignant 
colorectal disorders in this group may have confounded the results. Secondly we have assumed that 
the DNA we have isolated from the rectal mucus comes directly from the tumour, but exfoliated 
colonocytes from other areas of the colon along with blood and contaminates may have contributed 
to the specific methylation profile obtained in our samples. In addition, the high positive rates 
(resulting in marginally higher sensitivity and significantly lower specificity) we observed in our 
study compared to the previously published studies183,186,187 could be explained by  the way the 
methylation assay was calibrated using DNA extracted from stool instead of mucus as discussed in 
chapter 7, i.e. the methylation threshold might need to be raised for DNA isolated from mucus 
compared to that used for stool.
In summary, we have shown that it  is possible to sample and measure the DNA content of colonic 
mucus and that the best material to do so would be a foam based device in a shape that would be 
clinically  applicable (patient compliant, atraumatic etc) and that maximises the effective surface in 
contact with colonic mucus. There is a ‘volcano’ DNA exfoliation from tumours with DNA 
accumulating distally  in the rectum of CRC patients which can be sampled and isolated using a 
latex ballon device during standard proctoscopy. Unfortunately the three methylation marker panel 
we used was not able to reliably distinguish between CRC and controls in our study population. 
Further work (see below) will answer whether this failure was due to sampling technique or marker 
limitations.
90
Future work
This study has opened up numerous areas for future scientific and clinical research. 
It would be useful to establish the presence or absence of a gradient for the DNA in the MCL in 
different sections of the colon in healthy individuals. This would give all future studies a reference 
point. 
It would be interesting to use DNA from CRC tissue blocks in combination with matched rectal 
mucus DNA samples, to test for the presence of common genetic markers (e.g. Mutant APC, p53 
and KRAS, as the three most commonly found genetic markers in CRC) to confirm a correlation. If 
the two sets of DNA express the same markers, it will indicate that the DNA sampled in the rectum 
had originated from the tumour and therefore sampling rectal mucus is a technique worth exploring 
further as a method of CRC screening. 
Similarly  methylation markers could be compared between matched CRC tissue and rectal mucus 
specimens. Numerous methylation markers have been described and future may identify more 
appropriate markers to use in early colorectal neoplasia. 
Due to differential DNA yield between stool samples and rectal mucus samples, the methylation 
assays conditions and thresholds may need to be modified in order to obtain significant results. 
Large sample populations will be required in order to determine these parameters.
If these scientific studies show promising results the next step  will be to develop a device to sample 
rectal mucus which is well tolerated by patients and easy to use in clinic or at home. A device with a 
foam surface on a proctological instrument or catheter base would appear to be the most likely 
design but several prototypes will need to be tested. 
Although early detection of CRC is useful, screening ideally identifies adenoma prior to malignant 
transformation. Therefore large studies in conjunction with the current National Bowel Screening 
program should be undertaken in order to obtain enough patients with various stages of adenoma 
and to identify whether progressive genetic changes can be identified in their rectal mucus DNA.
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